

# Index

Terms that begin with numbers are indexed as if the number were spelled out; e.g., "3D models" is located as if it were spelled "ThreeD models."

A-87380

for influenza, 376

A-192558

for influenza, 376

Aablaquine, 934

**Abacavir**

anti-HIV drug, 471,472

selective toxicity, 267

ABELCET, 890,892

**Absidia**, 883

Absorption

of radiation energy, 153

**ABT-675**

for influenza, 376–377

Acedapsona, 830

ACE inhibitors

as antagonists, 251–252

**Achromycin**, 740,935

Acids

topical antibacterials, 551

**Actinobacter baumannii**

penicillin-binding protein,  
614,616

Actinocin

antitumor natural product,  
111

Adinomycin C

antitumor natural product,  
111

Actinomycin D

antitumor natural product,  
111

PLD repair inhibitor, 192

Actinomycins

antitumor natural products,  
111–115

Activator protein-1, 25

**Actonel**

selective toxicity, 273

Acyclovir

for hepatitis B virus, 331

for herpes virus, 305–326

selective toxicity, 254, 267

Acylides, 781–782

Adaptive immunity, 224–226

Adefovir

anti-HIV drug, 471,472

for hepatitis B virus, 332–333,  
334,335

for papillomavirus, 339

Adeno-associated viruses, 304

vectors for cancer gene ther-  
apy, 42

Adenoma-carcinoma, 4

S-Adenosyl-L-homocysteinehy-  
drolase inhibitors, 432–434

Adenoviruses, 303–304

antiviral agents, 340

dendritic cell transduction by,  
242

vectors for cancer gene ther-  
apy, 41–42

ADEPT (antibody-directed en-  
zyme-prodrug therapy), 83,  
87–90

Adozelesin

alkylating agent, 54, 61–64

**Adriamycin**

antitumor natural product,  
128

Adrucil

antimetabolite, 76

African trypanosomiasis (Afri-  
can sleeping sickness)

antiprotozoal agents for,  
1035–1045

**Aftate**, 891

**AG3340**

antiangiogenic agent, 217,218

**AG7088**

picornavirus antiviral,  
404–405

Agathisflavone

influenza antiviral agent, 389

Agonists, 250–251

AIDS, 458–459, 712. *See also*

Anti-HIV drugs; HIV pro-  
tease inhibitors; HIV virus

associated fungal infections,  
884

and malaria, 930

and tuberculosis, 823,824

AK-2123

radiosensitizer, 179

**D-Alanyl-D-alanine transpepti-  
dase**, 610

inhibition by  $\beta$ -lactams,  
611–612

Albendazole

antihelmintic, 1090–1091,  
1091

Alcohols

topical antibacterials, 547–548

Aldehydes

topical antibacterials, 551

Aldenosulfone, 830

Alemtuzumab, 229, 231–233

Alendronate

selective toxicity, 273

Alkeran

alkylating agent, 54

Alkylating agents

cyclopropylindoles, 54, 61–64

mustards, 52, 53–59

nitrosureas, 54, 64–65

platinum complexes, 54, 59–61

triazenes, 54, 65–67

Allegra

selective toxicity, 275

Allylamine antifungal agents,

890,891,899–900

Alvosulfon, 810

AM-1155,853

Amantadine, 361

anti-HIV drug, 469

selective toxicity, 266,267

Ambisone, 890,893

**AMD3100**

anti-HIV drug, 467

Amentoflavone

influenza antiviral agent, 389

American trypanosomiasis (**Cha-  
gas'** disease)

antiprotozoal agents for,  
1045–1047

**Ametrone**

topoisomerase II inhibitor, 69

Amidines

topical antibacterials, 554555

**Amikacin**, 748

antimycobacterial application,  
810,844

efficacy and dosage, 810

indications, 625

- Amikin**, 748,810
- 3-Aminobenzamide  
PLD repair inhibitor, 191–192
- 9-Aminocamptothecin  
antitumor natural product, 133
- 7-Amino-cephalosporanic acid,  
638–639
- Aminoglycoside antibiotics. *See*  
also Gentamicin; Neomycin;  
Streptomycin  
biosynthesis, 751–753  
clinical use and currently used  
drugs, 747–748  
drug resistance, 753–757  
pharmacology and mode of  
action, 749–751  
recent developments, 757–758  
selective toxicity, 260–261  
side effects, toxicity, and con-  
traindications, 748–749
- 8-Aminolaevulinic acid  
radiosensitizer, 175
- 3-Amino nocardinic acid deriv-  
atives, 660–663
- 6-Aminopenicillanic acid (6-APA)**  
compounds derived from, 609,  
630–637  
isolation and characterization,  
628–629  
structure-activity relation-  
ships, 630–637
- Aminopenicillins, 632  
use recommendations, 626
- p-Aminopropiophenone  
radioprotective agent, 165
- Aminopterin  
antimetabolite, 76, 78
- p-Aminosalicyclic acid**, 830–831  
efficacy and dosage, 810,863  
side effects, 831–832
- 3-Amino-1,2,4-triazole**  
radioprotective agent, 162
- 2-Amino-4,6,6-trimethyl-1,3-**  
thiazine  
radioprotective agent,  
164–165
- Amithiozone, 832
- Amodiaquine, 979  
antimalarial, 981–982  
dosage forms, 935
- Amopyroquine, 979
- Amorolfine, 903  
formulations and indications,  
891
- Amoxicillin**, 609
- Amoxicillin, 632  
antimycobacterial application,  
858  
in *vitro* antibacterial activity,  
635
- Amphocil, 890, 893
- Amphotec, 890, 893
- Amphotericin B, 889–893  
with flucytosine, 905  
formulations and indications,  
890, 891  
for leishmaniasis, 1051  
selectivity, 886
- Amphotericins  
selective toxicity, 268
- Amphoteric surfactants  
topical antibacterials, 557
- Ampicillin, 609, 632  
antimycobacterial application,  
858  
**pharmacokinetics**, 624  
use recommendations, 626
- Amprenavir  
anti-HIV drug, 475–476  
selective toxicity, 267
- Amsacrine**  
with etoposide, 71  
topoisomerase II inhibitor, 68,  
70
- Amsidyl  
topoisomerase II inhibitor, 68
- Anchorage-dependent growth,  
12–14, 21
- Ancistrocladine  
antimalarial, 994–995
- Ancobon**, 890
- Angiogenesis, 216  
and cancer, 20–21  
compounds inhibiting,  
216–220  
conditions related to, 220
- Angiogenic switch**, 20
- Angiostatin, 45
- Anhydrolides**, 781–782
- Anidulafungin, 888, 901,  
902–903
- Anionic surfactants  
topical antibacterials, 556–557
- Anisoactinomycins  
antitumor natural products,  
111
- Anoxia  
radioprotective agents utiliz-  
ing, 167–168
- Antagonists, 250–252
- Anthracyclines  
alkylating agents, 52  
antitumor natural products,  
110, 126–128
- Antiangiogenic agents, 38–39,  
216–220  
gene therapy approaches, 45
- Antiasthma drugs  
selective toxicity, 252
- Antibacterial agents, 538–539  
broad-spectrum  $\beta$ -lactams,  
705–709  
drug resistance, 543, 572–573,  
586, 590  
selective toxicity, 539, 443  
systemic synthetic, 557–596  
topical synthetic, 539, 457
- Antibiotic resistance, *See* Drug  
resistance
- Antibiotics, 738–739. *See also*  
Aminoglycoside antibiotics;  
Erythromycins; Macrolide  
antibiotics; specific types of  
Antibiotics, such as Tetracy-  
clines  
as antimalarials, 982–983  
antimycobacterial agents,  
840–853  
radioprotective agents, 166  
selective toxicity, 259–263
- Antibodies, 224–226  
general structure, 227
- Antibody-dependent cytotoxicity,  
225–226
- Antibody-directed **enzyme-pro-**  
drug therapy (ADEPT), 83,  
87–90
- Antibody-directed **immunother-**  
apy, 226–235
- Antibody-toxin conjugates  
(armed antibodies), 83,  
92–94  
selective toxicity (**paclitaxel**),  
258
- Anticancer drugs. *See also* Anti-  
tumor drugs; Cancer; Tu-  
mor-activated **prodrugs**  
**antiangiogenic** agents, 215–220  
drug resistance in chemother-  
apy, 281–290  
**electron-affinic** drugs in,  
180–183  
market for, 109  
radioprotective agents with,  
172–173  
selective toxicity, 257–259

- Anticancer gene therapy  
 approaches for, 43–46  
 prospects for, 39–43
- Anticoagulants  
 for cancer treatment, 38
- Antifolates, 76–79  
 antimalarial, 954–960
- Antifungal agents  
**allylamines**, 890, 891, 899–900  
 aureobasidins, 906–907  
**azoles**, 890, 891, **893–899**  
 benanomycins, 908  
 candins, 890, 900–903  
 epidemiology of resistance,  
 884–885  
 fungal efflux pump inhibitors,  
 909  
 miscellaneous compounds,  
 903–910  
 morpholines, 903  
 N-myristoyl transferase inhib-  
 itors, 908–909, 910  
 nikkomycins, 906  
 polyenes, 889–893, 890, 891  
 polyoxins, 906  
**pradimicins**, 908  
 selective toxicity, 254,  
 266–268, 886  
 sordarins, 907–908  
 thiocarbamates, 903  
 for treatment of superficial  
 cutaneous mycoses, 891  
 for treatment of systemic my-  
**coses**, 890  
 trends in, 910–911
- Antigen-presenting cells,  
 224–225, 235  
 and organ transplant rejec-  
 tion, 487
- Antihelminthics, 1090–1096
- Antihistamines  
 selective toxicity, 275–276
- Anti-HIV drugs. *See* also HIV pro-  
 tease inhibitors; HIV reverse  
**transcriptase** inhibitors  
 combination therapies, 479  
 drug resistance, 478–479  
 drugs in clinical use, 477–478  
 HIV vaccines, 465  
 inhibitors of **Gp120** binding to  
 T-cell receptors, 467–468  
 inhibitors of HIV gene expres-  
 sion, 473–474  
 inhibitors of HIV integrase,  
 465, 473  
 inhibitors of HIV-1 protease,  
 465, 475–477  
 inhibitors of HIV reverse tran-  
 scription, 465, 469–473  
 inhibitors of HIV ribonucle-  
 ase, 473  
 inhibitors of viral entry,  
 465–468  
 inhibitors of viral fusion,  
 468–469  
 inhibitors of viral maturation,  
 475–477  
 inhibitors of viral uncoating,  
 469  
 inhibitors of virion assembly,  
 474–475  
 need for new, 478–479  
 selective toxicity, 267  
 viral adsorption inhibitors,  
 465–467  
 virus "knock-out" strategy,  
 478–479
- Antiinfectives  
 selective toxicity, 259–263
- Anti-inflammatory** therapeutic  
 antibodies, 233–235
- Antimalarial agents  
 currently used drugs, 933–985  
 experimental agents, 985–993  
 natural products, 993–999  
 new targets, 993  
 resistance, 921, 928–930  
 selective toxicity, 254, 268
- Antimetabolites, 75–76  
 antifolates, 76–79  
 purine analogs, **76**, **81–82**  
 pyrimidine analogs, 76, 79–81
- Antimycobacterial agents,  
 809–813  
 antibiotics, 840–853  
 currently used drugs,  
 829–840  
 drugs under investigation,  
 853–860  
 future developments, 866–867  
 recent developments and  
 present status of chemo-  
 therapy, 860–867  
 screening and evaluation,  
 826–829  
 selective toxicity, 266
- Antioxidants, 33
- Antiparasitic drugs. *See* also An-  
 timalarial agents  
 antihelminthics, 1090–1096  
 selective toxicity, 254, 268
- Antiprotozoal agents, 1034–1035  
 for African trypanosomiasis,  
 1035–1045  
 for American trypanosomiasis,  
 1045–1047  
 for Leishmaniasis, 1047–1052  
 new drug therapy perspec-  
 tives, 1052–1076
- Antiradiation testing, 154
- Antisense oligonucleotides  
 HBV virus antiviral agents,  
 337  
 hepatitis C virus antiviral  
 agents, 415–417  
 influenza antiviral agents,  
 384–385
- Antisense technology  
 organ transplant rejection ap-  
 plications, 524–525
- Antiseptics, 539  
 testing, 544–545
- Antitumor drugs. *See* also Anti-  
 cancer drugs; Cancer; Tu-  
 mor-activated **prodrugs**  
 drug resistance in chemother-  
 apy, 281–290  
 macrolides, 784–785  
 radioprotective agents with,  
 172–173  
 selective toxicity, 257–259
- Antitumor natural products,  
 109–111  
 drugs attacking **DNA**, 110,  
 111–124  
 drugs inhibiting DNA process-  
 ing enzymes, 110, 124–136  
 drugs interfering with tubulin  
**polymerization/depolymer-**  
**ization**, 110, 136–143
- Antiviral agents. *See* also Anti-  
 HIV drugs  
 selective toxicity, 254, 266
- Antiviral agents, **DNA**, 305  
 adenoviruses, 340  
 for hepatitis B virus, 326–337  
 for herpesviruses, 305–326  
 papillomaviruses, 337–339  
 parvoviruses, 341–342  
 polyomaviruses, **339–340**  
 poxviruses, 340–341
- Antiviral agents, **RNA**, 360–361  
 arenaviruses, 430  
 broad spectrum, 432–435  
 flaviviruses, 427–430  
 hepatitis C virus, 361–364,  
 415–427  
 influenza A and B viruses,  
 364–390  
 measles virus, 390–396

- Antiviral agents, RNA (Continued)  
 orthopoxviruses, 435–440  
 parainfluenza virus, 390–398  
 paramyxovirus fusion proteins, 390–396  
 picornaviruses, 398–415  
 respiratory syncytial virus, 390–398  
 rotaviruses, 430–431  
 rubella virus, 431–432
- Apalcillin, 633
- AFC-6336  
 hepatitis C antiviral, 422–433
- APC (adenomatous polyposis coli) gene, 5–6, 27, 29–30  
 gene therapy target, 44–45  
 hypermethylation, 9
- Apicidin  
 antimalarial, 994
- Apoptosis  
 and adaptive immunity, 225  
 and carcinogenesis, 16–19  
 and drug resistance in cancer chemotherapy, 287–289
- Apoptotic tumor cells, 239
- AQ4N  
 radiosensitizer, 182  
 tumor-activated prodrug, 83, 84, 85
- Aralen, 934
- Arenaviruses  
 antiviral agents, 430
- Armed antibodies, 83, 92–94
- Arsumax, 935
- Arteannuin, 961
- Arteether, 964  
 antimalarial, 974–975  
 dosage forms, 935
- Arteflene  
 antimalarial, 984–985
- Artelinic acid, 964, 974–975
- Artemether, 964  
 antimalarial, 973–974  
 dosage forms, 935
- Artemisinin, 960–963  
 dosage forms, 935  
 first generation, 970–976  
 mechanism of action, 966–970  
 structure-activity relationship, 963–966
- 9-epi-Artemisinin, 965
- Artemotil, 935
- Arteries, 216
- Artesunate, 964, 972–973  
 dosage forms, 935
- Artificial organs, 526
- Asepsis, 539
- Asparenomycin A, 670, 671  
 in *vitro* activity, 692
- Aspergillosis, 883
- Aspergillus, 883, 884
- Aspergillus *fumigatus*, 882
- Aspirin  
 selective toxicity, 274
- Asulacrine  
 topoisomerase II inhibitor, 68–69, 71
- Ataxia telangiectasia, 32
- Atazanavir  
 anti-HIV drug, 476–477
- Atovaquone  
 antimalarial, 976–978  
 dosage forms, 935
- ATP-binding cassette genetic superfamily  
 and drug resistance, 285
- Augmentin, 695
- Aureobasidins, 906–907
- Aureomycin, 740
- Autolysins, 610–613
- Avloclor, 934
- Axin, 29–30
- Axisonitrile  
 antimalarial, 993
- Azadicarbonamide  
 anti-HIV drug, 469, 470
- Azapeptides  
 picornavirus antiviral, 408–409
- Azathioprine, 489, 490  
 clinical use for organ transplants, 513–516  
 side effects, 516
- 6-Azauridine  
 flavivirus antiviral, 427–428
- Azide  
 radioprotective agent, 162
- Azidocillin, 609
- Azithromycin, 763  
 antimalarial, 935, 983  
 antimycobacterial application, 857–858  
 selective toxicity, 261
- Azlocillin, 633  
 indications, 625  
 pharmacokinetics, 624
- Azolastone  
 alkylating agent, 54
- Azole antifungal agents, 890, 891, 893–899
- AZT. See Zidovudine
- Aztreonam, 609, 666  
 activity, 667  
 indications, 625  
 $\beta$ -lactamase classification based on activity, 620  
 pharmacokinetics, 624  
 side effects and interactions, 625  
 use recommendations, 626
- B-283, 838
- B-663, 838
- Bacampicillin, 609, 632
- Bacterial infections, 738
- Bacterial radiosensitizers, 197
- Bacterial resistance, See Drug resistance
- Bacterial ribosome, 738–739
- Bactrim, 934
- Bad protein, 24
- Bafilomycin A1  
 flavivirus antiviral, 429
- Bak protein, 19
- BANA compounds  
 antiviral application, 372–374
- Basal lamina, 216
- Basiliximab, 490, 510–513
- Batimastat, 217, 218
- Bax protein, 19
- Bay 12–9566  
 antiangiogenic agent, 217
- BBNH  
 anti-HIV drug, 473
- BBR 2778  
 topoisomerase II inhibitor, 68, 71
- BBR 3464  
 alkylating agent, 54, 61
- B-cell receptors, 224
- B-cells  
 and adaptive immunity, 224–225  
 exosome secretion, 241
- Bcl-2 protein, 22, 24, 26  
 and apoptosis, 19  
 and COX-2, 34  
 and drug resistance, 287, 288–289
- Bcl-x<sub>L</sub> protein, 19
- BCNU  
 alkylating agent, 54, 64–65
- Bcr-abl tyrosine kinase, 22
- BCX-1812  
 for influenza, 364, 374–376
- Benadryl  
 selective toxicity, 275
- Benanomycins, 908

- Benflumetol, 978  
 Benicillin, 632  
 Benzanthrone derivatives  
   RSV antiviral agents, 395  
 Benzimidazole antihelmintics,  
   1090–1093  
 Benznidazole  
   for American trypanosomiasis  
   (Chagas' disease),  
   1046–1047  
 Benzylpenicillin. *See also* Peni-  
   cillin G  
    $\beta$ -lactamase classification  
     based on activity, 619  
     structure, 628  
 Benzyl penicillin  
   *in vitro* antibacterial activity,  
   667  
 Betamipron, 693  
 Biapenem, 693  
   *in vitro* activity, 692  
 Bibenzimidazoles  
   radioprotective agents, 172  
**Bicyclam**  
   anti-HIV drug, 467  
 Bid protein, 19  
 Biguanides  
   topical antibacterials, 554–555  
**Bik** protein, 19  
 Biochemical shock  
   radioprotective agents, 169  
 Bioreductives (hypoxia-activated  
   prodrugs), 83–87  
   radiosensitizers, 181–182  
 Bisindolylmaleimides  
   influenza antiviral agents,  
   388–389  
 Bisphosphonates  
   selective toxicity, 273–274  
 Bistriazoloacridone  
   anti-HIV drug, 474  
 Bithionol  
   antihelmintic, 1091,  
   1095–1096  
 BL-1743  
   influenza antiviral agent, 388  
**Blastomyces dermatitidis**, 883  
 Blastomycosis, 883  
 Blenoxane  
   antitumor natural product,  
   115–120  
 Bleomycin  
   antitumor natural product,  
   110, 115–120  
   with tirapazamine, 85  
   with vinblastine, 140  
 Bleomycinic acid, 116–117, 118  
 Blood vessels  
   angiogenesis, 216  
   angiogenesis inhibiting com-  
   pounds, 216–220  
 Bloom's syndrome, 32  
 B-lymphocytes, *See* B-cells  
 BMS-40383, 680  
 BMS-40591, 680  
 BMS-45047, 681  
 BMS-45742, 680  
 BMS-181139, 680  
 BMS-181184, 908, 909  
 BMS-182880, 681  
 BMS-200475  
   for hepatitis B virus, 331–332  
 BMS-275291  
   antiangiogenic agent, 217  
 BMY-26270  
   influenza antiviral agent, 387  
 BMY-27709  
   influenza antiviral agent,  
   377–378  
 BMY-27946, 681  
 BMY-40732, 681  
 BMY-40886, 681  
 BMY-183021  
   influenza antiviral agent, 387  
**BMY-183355**  
   influenza antiviral agent, 387  
 Bone marrow transplantation  
   and organ transplant rejec-  
   tion, 524  
 Boron neutron capture therapy,  
   173–174  
 BRCA-1 gene, 8, 10, 27  
 BRCA-2 gene, 27  
 Breast cancer resistance protein,  
   285, 286  
 Brefeldin  
   rotavirus antiviral, 430  
 Brequinar, 489  
   clinical use for organ trans-  
   plants, 516–518  
   with leflunomide, 523  
   side effects, 518  
**Brivudin**  
   for herpes virus, 308  
 BRL-36650, 636–637  
 BRL-41897, 651–652  
 BRL-42715, 698–699  
   amoxicillin MIC, 695  
    $\beta$ -lactamase inhibitory activ-  
   ity, 695  
 BRL-44154, 634  
   *in vitro* antibacterial activity,  
   635  
 BRL-57342, 643  
 Broad spectrum antiviral agents,  
   432–435  
 Brobactam, 700  
 Bromodeoxyuridine  
   radiosensitizer, 194–195  
 Brusatol  
   antimalarial, 998  
 BTA-188  
   picornavirus antiviral, 402  
 Bulaquine, 953–954  
   dosage forms, 934  
 Bupivacaine  
   selective toxicity, 273  
 Bush classification, of  $\beta$ -lactam-  
   ases, 621  
**Butenafine**, 899–900  
   formulations and indications,  
   891  
 Butoconazole  
   formulations and indications,  
   891  
**B19** virus, 304  
 B-W 322, 490  
 C-1311  
   topoisomerase II inhibitor, 72  
 C22  
   influenza antiviral agent, 379  
 Cactinomycin-3, 111  
 Cadherins  
   and carcinogenesis, 8, 10  
   hypermethylation, 9  
   targets of antiangiogenic  
   agents, 220  
 Caffeine  
   radiosensitizer, 193  
 Calcium  
   and cancer prevention, 33  
 Calmette-Guerin, 819  
**Campath**, 229, 233  
**Camptotheca acuminata**, 130  
 Camptothecins  
   antitumor natural products,  
   110, 130–134  
**Canaline**  
   antimalarial, 987, 988  
 Cancer. *See also* Anticancer  
   drugs; Antitumor drugs;  
   Carcinogenesis; Oncogenes  
   drug resistance in chemother-  
   apy, 281–290  
   electron-affinic drugs in che-  
   motherapy, 180–183  
   epigenetic changes, 7–10  
   genes related to, 21–32  
   and genetic instability, 19–20  
   and genetic variability, 5–7

- Cancer (Continued)  
 heritable syndromes, 32  
 impact of, 2  
 interventions, 32–46  
 molecular basis of phenotypes, 10–21  
 prevention strategies, 32–33  
 radioprotective agents in therapy, 172–173  
 selective toxicity in chemotherapy, 257–259  
 tumorigenesis, 2–3, 5–7
- Candida, 890, 900–901
- Candida, 882, 883  
 diagnostic and microbiological issues, 885  
**intrinsic** resistance to antifungals, 885
- Candida albicans, 882, 883  
 biosynthesis and function of ergosterol, 886–888
- Candida *glabrata*, 882
- Candida *krusei*, 882
- Candida *parapsilosis*, 882
- Candida tropicalis, 882
- Candidiasis, 882, 883
- Candin** antifungal agents, 890, 900–903
- Capreomycin  
 antimycobacterial application, 811, 844–846  
 efficacy and dosage, 811, 863  
 side effects, 845–846
- Capstat**, 811
- Carbacephalosporins, 654
- Carbacephems  
 brief description, 609
- Carbapenams  
 brief description, 609
- Carbapenems, 668–671  
 anti-gram-positive, 703–705  
 biological properties, 688–694  
 brief description, 609  
 p-lactamase inhibitors, 699–700  
 orally active, 709–710  
**pharmacokinetics**, 623–624  
 polycyclic, 683–688  
 synthesis, 671–675  
 use recommendations, 626
- Carbecillin, 609
- Carbenicillin, 632  
 indications, 625  
 **$\beta$ -lactamase** classification based on activity, 619, 620, 621  
**pharmacokinetics**, 624
- Carbonic **anhydrase** inhibitors  
 selective toxicity, 264
- Carboplatin  
 alkylating agent, 54, 59  
 with **RSR13**, 190  
 selective toxicity, 257–258
- Carboxylic 3-deazaadenosine  
 activity against **orthopoxviruses**, 439, 440
- Carcinogenesis**, 3–5  
 and apoptosis, 16–19  
 and diet, 7  
 and DNA repair, 4, 5  
 epigenetic changes, 7–10  
 and ionizing radiation, 4, 33  
 and transforming growth factor  $\beta$ , 30–32
- Caretakers, 26
- Carfecillin, 609
- Carmustine  
 alkylating agent, 54, 64–65
- Carpetimycin A**, 670, 671
- Carumonam**, 666  
 in *vitro* activity, 667
- Carzelesin  
 alkylating agent, 54, 61–64
- Caspase-3  
 and apoptosis, 18
- Caspase-6  
 and apoptosis, 18
- Caspase-7  
 and apoptosis, 18
- Caspase-8  
 and apoptosis, 17–18
- Caspase-9  
 and apoptosis, 18, 19
- Caspases, 17–19
- Casporfungin, 888, 900–901  
 formulations and indications, 890
- Catharanthus *roseus*, vinca alkaloids from, 139
- Cationic** dyes  
 radiosensitizers, 175
- Cationic** surfactants  
 topical antibacterials, 555–556
- CB-1954  
 tumor-activated **prodrug**, 83, 91–92
- CB-3717  
 with perimetrexed, 77
- CC-83  
 antimalarial, 957
- CC-1065  
 alkylating agent, 61  
 for arming antibodies, 94
- CCNU  
 alkylating agent, 54, 64–65
- CDK-4 gene, 27
- cDNA** microarray chips  
 cancer studies using, 35–37
- CD8-positive** cytotoxic T-lymphocytes, 224–225
- CD4-positive T-helper cells, 224
- CDRI 80/53**, 953–954
- CDRI 871209**, 942
- Cefaclor, 609, 639, 640  
 activity, 644  
 oral absorption, 623  
 synthesis, 646–649
- Cefadroxil  
 oral absorption, 623
- Cefamandole, 609, 639–640  
 activity, 644  
 pharmacokinetics, 624
- Cefazolin, 639  
 activity, 644  
**pharmacokinetics**, 624
- Cefepime  
 activity, 641–642, 643, 644  
**pharmacokinetics**, 624  
 use recommendations, 627
- Cefixime**  
 activity, 640, 643, 644
- Cefmetazole, 651  
 synthesis, 650
- Cefonicid  
 pharmacokinetics, 624
- Cefoperazone  
 activity, 640, 641  
**biliary** excretion, 623  
 indications, 625  
**pharmacokinetics**, 624  
 use recommendations, 627
- Cefotaxime  
 activity, 640, 641, 644  
 p-lactamase classification based on activity, 620  
**pharmacokinetics**, 624
- Cefotetan, 651  
 activity, 640, 641  
 use recommendations, 627
- Cefoxitin, 609, 651  
 activity, 640  
 use recommendations, 627
- Cefpirome  
 activity, 641–642, 643, 644
- Cefprozil  
 selective toxicity, 269
- Cefratrizine  
 oral absorption, 623
- Cefsulodin  
 activity, 640, 642

- Ceftazidime  
 activity, 640, 642, 644, 667  
 indications, 625  
**pharmacokinetics**, 624  
 use recommendations, 627
- Ceftizoxime  
**pharmacokinetics**, 624
- Ceftriaxone  
 activity, 640, 641, 644  
 biliary excretion, 623  
 indications, 625  
**pharmacokinetics**, 624  
 use recommendations, 627
- Cefuroxime, 609, 639-640  
 activity, 644  
**pharmacokinetics**, 624  
 use recommendations, 627
- Cefuroxime axetil, 639, 640
- Celebrex  
 selective toxicity, 274
- Celecoxib  
 selective toxicity, 274
- CellCept**, 519, 520
- Cell cycle  
 changes in carcinogenesis,  
 14-16
- Cell proliferation, 4
- Cell suicide, See Apoptosis
- Central nervous system (CNS)  
 drugs, See CNS drugs
- Cephacins, 638  
 synthesis, 649-650
- Cephalexin, 639  
 activity, 644  
 oral absorption, 623  
 synthesis, 646-649
- Cephaloglycine  
 oral absorption, 623
- Cephalolexin, 609
- Cephaloridine  
 **$\beta$ -lactamase** classification  
 based on activity, 620, 621
- Cephalosporin C, 609  
 derivatives, 638-639  
 discovery, 637  
 total synthesis, **645-649**
- Cephalosporins, 637-639  
 anti-gram-positive, 703  
 antimycobacterial application,  
 858  
 carbacephalosporins, 654  
 C7-a-formamido derivatives,  
 651-652  
 C7-a-methoxylated deriva-  
 tives, 650-651  
 oxacephalosporins, 652-654  
**pharmacokinetics**, 623  
 selective toxicity, 253-254,  
 260  
 side effects and interactions,  
 624-625  
 structure-activity relationship,  
 639-645  
 use recommendations, 627
- Cephalosporium** acremonium,  
 609, 637
- Cephalothin, 609, 639  
 activity, 644  
 indications, 625  
**pharmacokinetics**, 624
- Cephamycins, 609, 634, 638  
 synthesis, 649
- Cephazolin, 609
- Cephems  
 brief description, 609
- Cephradine  
 oral absorption, 623  
 pharmacokinetics, 624
- Cerubidine  
 antitumor natural product,  
 126-128
- CGP 37697, 660
- CGP 51905A**  
 antimalarial, 987, 988
- CGS 27023A**  
 antiangiogenic agent, 217
- Chagas'** disease (American  
 trypanosomiasis)  
 antiprotozoal agents for, 1035,  
 1045-1047
- Chalicheamicin-type DNA cleav-  
 ing agents, 92
- Chemokines**  
 production in T-cell activation  
 by dendritic cells, 235
- Chemotherapy, 538
- L-Chicoric acid  
 anti-HIV drug, 473, 474
- Chimeric antibodies, 226
- Chinchonism, 937
- Chirality  
 and selective toxicity, 268-273
- Chloproguanil  
 antimalarial, 954-956
- Chlopromazine  
 radioprotective agent, 165
- Chloprothixene  
 radioprotective agent, 165
- Chlorambucil  
 alkylating agent, 53, 54
- Chloramphenicol, 789-792
- Chlorine topical antibacterials,  
**545-547**
- Chlormidazole, 893-897
- Chlorocardin, 661
- 2-Chloro-2'-deoxyadenosine  
 antimetabolite, 76
- Chloroquine  
 antimalarial, 938-943  
 dosage forms, 934  
 resistance to, 921, 928-930
- Chlorothiazide  
 selective toxicity, 264
- Chlorpheniramine  
 selective toxicity, 275
- Chlorproguanil  
 with dapsone, 959  
 dosage forms, 934
- Chlorpromazine  
 arenavirus antiviral, 430
- Chlorpropamide  
 selective toxicity, 264
- Chlortetracycline, 740, 742
- Chlor-Trimetron  
 selective toxicity, 275
- Chromatin remodeling, 8
- Chromomycosis, 883
- Chromosomes  
 acquisition of extra, and **carci-**  
 nogenesis, 19
- Chromosome X inactivation  
 and carcinogenesis, 8
- Chrysophanic acid  
 picornavirus antiviral, 414
- Chrysosplenol C  
 picornavirus antiviral, 413
- Cialis  
 selective toxicity, 277
- Ciclopirox, 906  
 formulations and indications,  
 891
- Ciclosporine**, 490, 491
- Cidofovir  
 for adenoviruses, 340  
 for herpes virus, 308, 317  
 for orthopoxviruses, 439  
 for papillomavirus, 338339  
 for polyomaviruses, 339  
 for poxviruses, 341  
 selective toxicity, 267  
 for smallpox, 437-440
- Cilastin  
 coadministration with **imi-**  
**penem**, 623, 693
- Cilofungin**, 901
- Cimetidine  
 selective toxicity, 275
- Cinchona bark, quinine from,  
 933
- Cinchonidine, 933
- Cinchonine, 933

- Ciprofloxacin, 853–855  
antimalarial, 935,983
- Cisplatin  
alkylating agent, 54, 59  
with gemcitabine, 80, 81  
with ionizing radiation, 196  
with nolatrexed, 79  
with permetrexed, 78  
selective toxicity, 257–258  
structure-activity relationship, 60–61  
with tirapazamine, 86  
with vinblastine, 140
- Cisplatin rescue, 172
- CL-61917  
influenza antiviral agent, 378
- CL-191121, 709
- CL-253824  
for herpes virus, 314
- CL-309623  
RSV antiviral agent, 390393
- CL-387626  
RSV antiviral agent, 390–393
- Cladosporium, 883
- Cladribine  
antimetabolite, 76, 81–82
- Clarithromycin, 763  
antimycobacterial application, 856–857  
selective toxicity, 261
- Claritin  
selective toxicity, 275
- Clavulanic acid, 609  
**amoxicillin** MIC, 695  
antimycobacterial application, 858  
discovery, 694–697  
indications, 625  
 **$\beta$ -lactamase** inhibitory activity, 695  
use recommendations, 626
- Cleland's reagent  
radioprotective agent, 156–157
- Cleocin, 935
- Cleomycins  
antitumor natural products, 115,117
- Clevudine  
for hepatitis B virus, 327, 329–330
- Clindamycin, 788–789  
antimalarial, 935,984
- Clinical reaction modifiers, 152.  
See also Radioprotective agents; Radiosensitizers
- Clociguanil, 960
- Clofazimine, 837–839  
efficacy and dosage, 810  
side effects, 839
- Clomiphene  
selective toxicity, 268
- Clotrimazole, 893–897,959  
formulations and indications, 891  
selective toxicity, 268
- Cloxacillin, 631  
in *vitro* antibacterial activity, 635
- CMDA  
tumor-activated **prodrug**, 87–88
- C-myc protein, 25–26  
and APC gene, 30  
cDNA microarray studies, 37
- CNI-H0294  
**antimalaria**8, 987
- CNS drugs  
radioprotective agents, 165
- Coartem, 935
- Coccidioides immitis, 883
- Coccidioidomycosis, 883
- Colchicine  
radioprotective agent, 165
- Cold sores, 298
- Collagenases, 13
- Collagen I, 216
- Collagen 111,216
- Collagen N, 12,216
- Collagen VII, 216
- Combined modality therapy, 173
- Combretastatin  
tumor-activated **prodrug**, 87
- Combretastatin A4, 219, 220
- Complementarity determining regions, 227
- Conjugative transposons, 614, 616
- Copper complexes  
radioprotective agents, 163
- Cord-factor, 817
- Cordycepin  
PLD repair inhibitor, 192
- Cosalane  
anti-HN drug, 466
- Cosmegen  
antitumor natural product, 111–115
- Costimulatory signals, 487  
agents capable of inhibiting, 525–526
- Cotrifazid, 959
- Cotrim, 934
- Cotrimoxazole  
systemic antibacterial, 596
- COX-1  
and cancer, 34
- COX-2  
and cancer, 33–35
- COX-1 inhibitors  
selective toxicity, 252, 274–275
- COX-2 inhibitors. See also Leukotrienes  
selective toxicity, 274–275
- CP 70429,660
- CpG island methylated phenotype (CIMP), 289
- CPT-11  
antitumor natural product, 131
- Cruex, 891
- Cryptococcal meningitis, 884
- Cryptococcosis, 883
- Cryptococcus* neoformans, 883, 884  
diagnostic and microbiological issues, 885
- Cryptolepine  
antimalarial, 998–999
- CS-834, 709–710
- CTLA4-Ig, 525–526
- Cyanide  
radioprotective agent, 162
- Cyclacillin, 632
- Cyclin dependent kinases  
in carcinogenesis, 14–16  
and organ transplant rejection, 487
- Cyclins  
in carcinogenesis, 14–16  
and organ transplant rejection, 487
- Cycloguanil, 955,956
- Cyclooxygenase 1/2 inhibitors,  
See COX-1 inhibitors;  
COX-2 inhibitors
- Cyclophosphamide  
alkylating agent, 53, 54, 55–56  
with AQ4N, 85  
with dactinomycin, 111  
with daunorubicin, 126  
with MEA as radioprotective agent, 172  
**as prodrug**, 83  
with tirapazamine, 85  
tumor-activated **prodrug**, 91
- Cycloprodigosin  
antimalarial, 994



- Cyclopropylindoles**  
alkylating agents, 54, 61–64
- Cyclopropylindolines**  
alkylating agents, 52
- Cycloserine**  
antimycobacterial application, 811, 846  
efficacy and dosage, 811, 863  
side effects, 846
- Cyclosporine**  
clinical use for organ transplants, 489–494  
with leflunomide, 523  
pharmacokinetics, 491–492  
pharmacology, 492–494  
side effects, 494  
structure-activity relationship, 494
- Cyclosporine A**  
multidrug resistant protein inhibition, 290
- Cysteamine**  
radioprotective agent, 152, 155–160
- Cysteine**  
radioprotective agent, 152, 155
- Cytallene**  
for hepatitis B virus, 330
- Cytochrome c**  
and apoptosis, 17
- Cytokines**  
in cancer, 43  
production in T-cell activation by dendritic cells, 235  
radioprotective agents, 171  
radiosensitizers, 194  
tumor secreted, 226
- Cytomegalovirus**, 298
- Cytomegalovirus antiviral drugs**  
selective toxicity, 267
- Cytoplasmic proteins**, 26
- cytosar**  
antimetabolite, 76
- Cytosine arabinoside**  
antimetabolite, 75, 76, 79–82
- Cytosine deaminase tumor-activated prodrugs**, 90–91  
for cancer therapy, 44
- Cytotoxic drugs**, 52, 82, 109. *See also* Antitumor drugs; Tumor-activated prodrugs
- Cytotoxic T-lymphocytes**, 224–225
- Cytovene**  
tumor-activated prodrug, 83
- cytoxan**  
alkylating agent, 54
- DA-1131, 708
- DACA**  
dual topoisomerase I/II inhibitor, 68, 73
- DACA N-oxide**, 85
- Dacarbazine**  
alkylating agent, 54, 65–66
- Daclizumab**, 490, 510–513  
with mycophenolate mofetil, 520
- Dactinomycin**  
antitumor natural product, 110, 111–115
- Dapsone**, 936, 957  
antimycobacterial application, 829–830  
with chlorproguanil, 959  
dosage forms, 934  
efficacy and dosage, 810  
with proguanil, 959  
with pyrimethamine, 959
- Daraprim**, 934
- Darvon**  
selective toxicity, 269–270
- Daunomycin**  
antitumor natural product, 126–128, 130
- Daunorubicin**  
antitumor natural product, 110, 124, 126–128
- Death domain**, 17
- Death effector domain**, 17
- Death-inducing signaling complex**, 17
- Death receptors**, 17
- 3-Deazaneplanocin A**  
activity against orthopoxviruses, 439, 440  
for Ebola virus, 433
- Declomycin**, 740
- Decontamination**, 539
- Delavirdine**  
anti-HIV drug, 472  
selective toxicity, 267
- Deltaprim**, 934
- Demethylchlortetracycline**, 740
- 5'-O-Demethyldioncophylline A**  
antimalarial, 994–995
- Dendritic cell immunotherapy**, 235–243
- Dendritic cells**  
and adaptive immunity, 224  
physiology, 235–236  
T-cell activation by, 235–236  
transduction by viral vectors, 241–243  
tumor cell fusion, 240–241
- Dengue fever**, 1035
- Dengue virus**, 427
- Deoxoartemisinin**, 964
- Deoxyartemisinin**, 963
- 2'-Deoxycoformycin**  
antimetabolite, 76
- 15-Deoxyspergualin**, 489, 490  
antimalarial, 987  
clinical use for organ transplants, 504–506  
with leflunomide, 523  
side effects, 506
- Dermatophytoses**, 883
- Desciclovir**  
for herpes virus, 318
- Desenex**, 891
- Desferrioxamine B (DFO)**  
antimalarial, 991
- Desmethylmisonidazole**  
radiosensitizer, 178
- Dexamisole**  
selective toxicity, 273
- Dexrazoxane**  
radioprotective agent, 172
- Dextrans**  
radioprotective agent, 166
- Dextromethorphan**  
selective toxicity, 255
- Dextropropoxyphene**  
selective toxicity, 269–270
- DFO**, *See* Desferrioxamine B
- DHFR**, *See* Dihydrofolate reductase
- Diaminopyrimidines**  
selective toxicity, 263–264
- Diarylureas**  
topical antibacterials, 554–555
- Diazenes**  
radiosensitizers, 192–193
- Dibenzofurans**  
**picornavirus** antiviral agents, 403
- Dibenzosuberanes**  
**picornavirus** antiviral agents, 403
- Dicloxacillin**, 631
- Didanosine**  
anti-HIV drug, 471, 472  
selective toxicity, 267
- Diet**  
for cancer prevention, 33  
and carcinogenesis, 7
- Diethylcarbamazine**  
antihelminthic, 1091, 1095–1096
- Diethylmaleate**  
radiosensitizer, 190–191

- Difluoromethylornithine, 35
- Digoxin**  
with bleomycin, 116
- Dihydroartemisinin**, 963,  
971–972  
dosage forms, 935
- Dihydrofolate reductase  
antimalarial target, 925  
increased expression leading  
to drug resistance in cancer  
chemotherapy, **283–284**
- Dihydrofolate reductase inhibi-  
tors  
antimetabolites, 76–78  
selective toxicity, 264
- Dihydroorotate dehydrogenase  
antimalarial target, 925
- Dihydropteroate **synthetase** in-  
hibitors  
antimalarials, 925  
selective toxicity, 264
- Dihydrostreptomycin, 841
- Diiodofluorescein  
influenza antiviral agent, 379
- 2,6-Diketopiperazine** derivatives  
influenza antiviral agents,  
386–387
- Dimeric vinca alkaloids  
antitumor natural product,  
139–143
- Dimethyl fumarate**  
radiosensitizer, 193
- Dimethyl sulfoxide (DMSO)**  
radiosensitizer, 176
- Dioncolactone A  
antimalarial, 994–995
- Dioncopeltine A  
antimalarial, 994–995
- Dioncophylline B  
antimalarial, 994–995
- Dioncophylline C  
antimalarial, 994–995
- 2,4-Dioxobutanoic acid** deriva-  
tives  
influenza antiviral agents, 386
- Diphenhydramine  
selective toxicity, 275
- 2,3-Diphosphoglycerate**  
(**2,3-DPG**)  
radiosensitizer, 183–184
- Diphtheria toxin  
selective toxicity, 259
- Dirithromycin, 763
- Disinfectants, 539  
testing, 544
- Disoxaril  
picornavirus antiviral, 400
- Ditercalinium  
dual topoisomerase **H I** inhibi-  
tor, 75
- Dithiothreitol  
radioprotective agent,  
156–157
- DK-35C**, 706, 708
- DMP 840  
dual topoisomerase **H I** inhibi-  
tor, 68, 75
- DMSO, *See* **Dimethyl sulfoxide**
- DMXAA**  
with **tirapazamine**, 85
- DNA-binding drugs. *See also*  
Alkylating agents  
antitumor natural products,  
**111–124**  
chemotherapeutic agents and  
related tumor-activated  
**drugs**, 51–94
- DNA **gyrase** inhibitors  
selective toxicity, 263
- DNA hypermethylation  
and drug resistance, 289  
and epigenetic changes, 8–10
- DNA hypomethylation, 8
- DNA-intercalating **topoisomer-**  
ase inhibitors, *See* **Topo-**  
isomerase **II** inhibitors; **Topo-**  
isomerase **I** inhibitors
- DNA lesions, 4, 176
- DNA methylation  
accumulation, 3  
and drug resistance, 289  
and epigenetic changes, 8–10
- DNA methyltransferases, 8
- DNA polymerases, **295–296**
- DNA radicals, 176–180
- DNA repair  
and carcinogenesis, 4, 5  
and drug resistance in cancer  
chemotherapy, 287  
enhancement by **radioprotec-**  
tive agents, 169–170  
inhibition by radiosensitizers,  
191–193
- DNA repair-deficiency diseases,  
32
- DNA topoisomerase 1, *See* **Topo-**  
isomerase **I**
- DNA topoisomerase 2, *See* **Topo-**  
isomerase **II**
- DNA viruses, 294–295. *See also*  
Antiviral agents, DNA
- DNAzymes**  
influenza antiviral agents,  
385–386
- Docetaxel  
antimalarial, 990  
antitumor natural product,  
110, 137, 138–139
- Dolastatin 10, 140
- Donor bone marrow  
organ transplant rejection ap-  
plications, 524
- L-Dopa  
selective toxicity, 273
- Dopaminergic receptors  
and selective toxicity, 259
- Dose reduction factor, **radiopro-**  
tective agents, 154
- Double minute chromosomes, 20
- Doxycyclin, 935
- Doxepin  
selective toxicity, 268–269
- DOX-GA3**, 90
- Doxorubicin  
with amsacrine, 68  
antibody conjugates, 92  
antitumor natural product,  
83, 110, 124, 128, 129  
resistance to, 288  
tumor-activated **prodrug**, 88,  
89–90
- Doxycyclin**, 740
- Doxycycline**, 740, 742  
antimalarial, 935, 982
- Dramamine  
selective toxicity, 275
- Drug detoxification, **286–287** .
- Drug resistance  
aminoglycoside antibiotics,  
753–757  
antibacterial agents, 543,  
572–573, 586, 590  
antifungal agents, 884–885  
anti-HIV drugs, 478–479  
antimalarial agents, 921,  
928–930  
antimycobacterial agents,  
860–861  
in cancer chemotherapy,  
281–290  
HBV virus antiviral agents,  
333–334  
herpes virus antiviral agents,  
309–310  
to  **$\beta$ -lactams**, 613–623  
linezolid, 590  
macrolide antibiotics, 774–776  
quinolones, 586  
sulfonamides and sulfones,  
**572–573**  
tetracyclines, 743–746

- DTIC  
alkylating agent, 54, 65
- DU-86  
alkylating agent, 61
- DU-257  
tumor-activated **prodrug**, 83, 94
- Duocarmycin  
for arming antibodies, 94
- DuP-721  
antimycobacterial, 859
- DX-8739, 682
- DX-8951f  
antitumor natural **product**, 133
- Dyes  
topical antibacterials, 553–554
- Ebola virus, 432–434
- E-cadherin, 8, 10, 14  
hypermethylation, 9
- Echinocandins  
antifungals, 900–903
- Econazole, 893–897  
formulations and indications, 891
- Edatrexate  
antimetabolite, 76, 78
- EDTA, See **Ethylenediaminetetraacetic acid**
- Efaproxiral  
radiosensitizer, 184–190
- Efavirenz  
anti-HIV drug, 472  
selective toxicity, 267
- Eflornithine  
for African trypanosomiasis, 1043–1045
- EICAR  
flavivirus antiviral, 428
- Electron-affinic** drugs, 180–183
- Ellece  
antitumor natural product, 128
- Elutherobin  
antitumor activity, 139
- Embryonic stem cells, 524
- EMD121974  
antiangiogenic agent; 218–219
- Emerging pathogens, 713
- Emivirine  
anti-HIV drug, 472
- Emtricitabine  
for hepatitis B virus, 327, 329
- Enamelysin, 13
- Enbrel, 229, 234
- Endostatin, 45
- Endothelial cells, 216  
cytoskeleton disruptors, 219–220  
inhibitors of migration, 219
- Entecavir  
for hepatitis B virus, 331–332
- Enterococcus  
bridge in peptidoglycans, 612  
methicillin-resistant, 618  
penicillin-binding protein, 615  
porin loss in, 621
- Envirodene  
picornavirus antiviral, 411
- Enviroxime  
picornavirus antiviral agent, 411–413
- Epicillin, 632
- Epidermal growth factor  
decreased dependence on in carcinogenesis, 11  
radiosensitizer, 194
- Epidermal growth factor receptor, 11, 23
- Epigenetic changes  
and carcinogenesis, 7–10  
and drug resistance in cancer chemotherapy, 289
- Epipodophylloxins  
alkylating agents, 52
- Epirubicin  
antitumor natural product, 110, 124, 128  
tumor-activated **prodrug**, 89
- Epothilones  
alkylating agents, 52  
antitumor activity, 139
- Epoxides  
topical antibacterials, 550–551
- Epstein **Barr** virus, 296–297, 299
- Erb-B1** growth factor receptor, 22, 23
- Erb-B2/HER2/neu** growth factor receptor, 22, 23
- Ergosterol  
biosynthesis by fungal pathogens, 886–888
- Erythrocytes  
exosome secretion, 241  
in malaria, 920–926
- Erythromycins, 763  
antimycobacterials, 855–858  
selective toxicity, 261–263
- Estrogen receptors  
hypermethylation and carcinogenesis, 9
- Estrogens  
radioprotective agents, 165
- Etanercept, 229, 234–235
- Etanidazole  
radiosensitizer, 178
- Ethambutol, 839–840  
drug interactions, 864  
efficacy and dosage, 810, 863  
side effects, 840
- Ethionamide, 835–836  
efficacy and dosage, 810, 863  
side effects, 836
- Ethylenediaminetetraacetic acid (**EDTA**)  
radioprotective agent, 163
- N-Ethylmaleimide  
radiosensitizer, 177
- Etopophos, 135
- Etoposide  
with amsacrine, 71  
antitumor natural product, 110, 134–135  
resistance to, 288  
with tirapazamine, 85  
tumor-activated **prodrug**, 87
- Evernimycin, 793
- Evista  
selective toxicity, 276
- Exelderm, 891
- Exifone**  
antimalarial, 987
- Exosomes, 241
- Extended-spectrum  **$\beta$ -lactamases**, 619
- External guide sequences  
influenza antiviral agents, 385–386
- Famciclovir  
for hepatitis B virus, 330–331  
for herpes virus, 309, 310  
selective toxicity, 267
- Fanconi's anemia, 32
- Fansidar, 934
- Fansimef, 934
- Faropenem, 659, 660
- Fas-associated death domain, 17
- Fas ligand  
and adaptive immunity, 225
- Fattiviracin **A1**  
influenza antiviral agent, 390
- FCE 22101, 659, 660
- FCE 22891, 659
- FCE 29464, 660
- Fd4C**  
for hepatitis B virus, 327, 329, 333
- Febrifugine  
antimalarial, 996, 997
- Femstat, 891
- Fenozan-50F  
antimalarial, 985–986

- Fenpropimorph, 903
- Ferricinium salts  
radiosensitizers, 196
- Ferrochloroquine  
antimalarial, 992
- Fetal stem cells, 524
- Fexofenadine  
selective toxicity, 275
- Fibroblast growth factor,  
217–218
- Fibroblast growth factor inhibi-  
tors  
antiangiogenic agents,  
218–219
- Fibronectin, 12, 216, 219
- Fiflucan, 890
- FK 463, 888, 902, 903
- FK 506  
clinical use for organ trans-  
plants, 494–500  
pharmacokinetics, 495  
pharmacology, 495–499  
side effects, 500  
structure-activity relationship,  
499–500
- FK-506 binding protein, 496
- Flaviviruses**, 427  
antiviral agents, 427–430
- Flomoxef, 652–653
- Flucloxacillin, 609, 631
- Fluconazole, 893–897  
formulations and indications,  
890  
intrinsic resistance to, 885  
selective toxicity, 268
- Flucytosine, 903–905  
formulations and indications,  
890
- Fludara  
antimetabolite, 76
- Fludarabine  
antimetabolite, **76, 81–82**
- 5-Fluoroorotate  
antimalarial, 987, 988
- Fluoroquinoline K-12  
anti-HIV drug, 474
- Fluoroquinolones  
antimycobacterials, 853–855  
selective toxicity, 263  
side effects, 855
- 5-Fluorouracil  
antimetabolite, 75, 76, 77,  
79–81  
with ionizing radiation, 195  
with irinotecan, 131  
with oxaliplatin, 60  
with papillomavirus, 338
- resistance to, 284, 288  
tumor-activated **prodrug**, 44,  
90–91
- Fluosol  
radiosensitizer, 183
- Flurithromycin, 763
- Flutimide  
influenza antiviral agent,  
**386–387**
- Fms growth factor receptor, 22
- FNQ3**  
flavivirus antiviral, 429–430
- Folate analog antimetabolites,  
76–79
- Fomivirsen  
for herpes virus, 309
- Fonsecaea*, 883
- Formadecins, 664
- Formidacillin, 636–**637**  
in *vitro* antibacterial activity, 635
- Fosamax**  
selective toxicity, 273
- Foscarnet**  
for herpes virus, 308  
selective toxicity, 267
- Fosmidomycin  
antimalarial, 989
- Fos protein, **22, 25**
- FR191512**  
influenza antiviral agent, 390
- FR900098**  
antimalarial, 989
- FR901379, 902**
- Free radicals  
inhibition by radioprotective  
agents, 168  
production by ionizing radia-  
tion, 153
- FTY 720, 489  
clinical use for organ trans-  
plants, 506–509  
side effects, 509
- Fullerene C<sub>60</sub>  
influenza antiviral agent, 390
- Fumigation, 539
- Fungal cell wall, 888–889
- Fungal diseases, 882–884. See  
also Antifungal agents  
diagnostic and microbiological  
issues, 885–886  
trends in incidence, 884
- Fungal** efflux pump inhibitors, 909
- Fungal pathogens, 882–884  
biosynthesis and function of  
ergosterol, 886–888  
opportunistic filamentous, 884
- Fungi, 882
- Fungizone, 890, 891
- Furosemide  
selective toxicity, 264
- Fusidic acid, 792
- Gamma rays  
antiradiation testing, 154
- Ganciclovir  
for hepatitis B virus, 330–331  
for herpes virus, 307–308  
with HSV-based suicidal gene  
therapy, 44  
tumor-activated **prodrug**, **83, 90**
- Gantanol, 934
- Gantrisin, 934
- Gatekeepers, 26
- GDEPT (gene-directed enzyme-  
**prodrug** therapy), **83, 90–92**
- Gedunin  
antimalarial, 996, 998
- Gelatinases, 13
- Gemcitabine  
antimetabolite, 76, 80–81  
with perimetrexed, 78  
radiosensitizer, 195
- Gemtuzumab, 228, 231–233
- Gemtuzumab **ozogamycin**  
tumor-activated **prodrug**, 83,  
92
- Gemzar  
antimetabolite, **76, 80**
- GeneChips**, 35
- Gene-directed enzyme-prodrug  
therapy (**GDEPT**), 83,  
90–92
- Gene silencing  
and carcinogenesis, 8
- Gentamicin, 748
- Gentamycin, 748  
selective toxicity, 260–261
- Glabranine  
flavivirus antiviral, 429
- Glaucine fumarate  
picornavirus antiviral, 414
- Gleevec, 110, 284  
selective toxicity, 257
- Glimepiride  
selective toxicity, 264
- Gliotoxin  
hepatitis C antiviral, 426
- Glipizide  
selective toxicity, 264
- Gloximonam, 666, 668
- Glucocorticoid response ele-  
ments  
and oncogenes, 25

- Glucose 6-phosphate **dehydrogenase**  
and malaria, 931
- Glucosulfone sodium, 829
- Glucuronidase tumor-activated prodrugs, 89–90
- Glutathione  
radiosensitization by depletion of, 190–191
- Glyburide  
selective toxicity, 264
- Glyphosate  
antimalarial, 988–989
- GM 237354, 907–908
- Gp100, 237–238
- Gp120-CCR5 binding, 462  
inhibitors, 468
- Gp120 coreceptors, 467
- Gp120-CXCR4 binding, 462  
inhibitors, 467–468
- G proteins, 23–24
- GR69153, 643, 645
- Gram-negative bacteria  
action of  $\beta$ -lactams against, 611–613  
cell wall, 610–611  
 $\beta$ -lactam indications, 625  
penicillin-binding protein, 614
- Gram-positive bacteria  
action of  $\beta$ -lactams against, 611–613  
cell wall, 610–611  
 $\beta$ -lactam indications, 625  
penicillin-binding protein, 615
- Granule enzymes, 225
- Granulocytes  
and adaptive immunity, 225  
and innate immunity, 224
- Griseofulvin, 905–906  
formulations and indications, 891
- GS-4071  
for influenza, 370, 371, 473
- GS-4104  
for influenza, 368
- GTPase, 24
- GTPase-activating protein, 25
- Guanine nucleotide exchange factors, 22, 24
- Gusperimus, 490
- GV104326, 684, 685
- GV129606X, 687, 689, 694, 708
- GV143253X, 687, 690, 694, 705
- Gymnochrome D  
flavivirus antiviral, 429
- H-961  
for herpes virus, 321  
for poxviruses, 341
- Haemophilus *influenzae*  
penicillin-binding protein, 614, 616, 617
- Halfan, 934
- Halofantrine  
antimalarial, 946–949  
dosage forms, 934
- Halogenated topical antibacterials, 545–547
- Haloprogin, 906  
formulations and indications, 891
- Halotex, 891
- Ha-ras gene, 4
- Hayflick limit, 11
- HBB  
picornavirus antiviral, 413
- HCMV (cytomegalovirus), 298
- Heart transplantation, 487
- Heat shock proteins, 819
- Heavy metals  
topical antibacterials, 552–553
- Helicobacter Pylori, 740  
metronidazole-resistant, 712
- Helminths, 1090  
antihelmintics for, 1090–1096
- Heparin sulfate proteoglycans, 21, 216
- Hepatitis B virus, 297, 299–301
- Hepatitis B virus antiviral agents, 326  
antisense oligonucleotides, 337  
combination treatments, 334–335  
purines, 330–333  
pyrimidines, 326–330  
resistance, 333, 334  
targeting **drugs** to liver, 335–337
- Hepatitis C virus, 361–362  
and HBV infection, 300  
model systems to study replication, 427
- Hepatitis C virus antiviral agents  
inhibitors of HCV 5' untranslated region and core gene, 415–417  
inhibitors of NS5B RNA-dependent RNA polymerase, 425–426  
inhibitors of NS3 helicase, 425  
inhibitors of NS3 protease, 418–425  
interferon- $\alpha$  applications, 361–364
- Hepatitis C virus NS3 protein, 417–418
- Herceptin, 228, 230  
selective toxicity, 257
- Herpes simplex virus  
in suicidal gene cancer therapy, 44
- Herpes simplex virus-1, 297, 298
- Herpes simplex virus-2, 298
- Herpes virus antiviral agents, 305  
compounds under development, 310–326  
currently approved drugs, 305–310  
immune modulators, 325–326  
nucleoside inhibitors and other targets, 321–324  
**prodrugs** increasing oral availability, 309  
**prodrugs** under development, 318–321  
resistance to, 309–310  
selective toxicity, 267
- Herpes viruses, 294–295, 297–299
- $\alpha$ -Herpesviruses, 298
- $\beta$ -Herpesviruses, 298
- $\gamma$ -Herpesviruses, 298, 299
- Herpes virus **protease** inhibitors, 324–325
- Herpes zoster, 298
- Hesperidin  
rotavirus antiviral, 431
- Heterocyclic compounds  
radioprotective agents, 163–165
- 6-Heterocyclylmethylene penems, 698–699
- HHV-6, 298–299
- HHV-7, 298–299
- HHV-8, 299
- Highly active antiretroviral therapy (**HAART**), 884  
**HIV/AIDS**, 479
- Histone** deacetylases, 8
- Histoplasma capsulatum, 883
- Histoplasmosis, 883
- HIV-DNA polymerase (reverse **transcriptase**), 462–463
- HIV integrase inhibitors, 464
- HIV protease, 464

- HIV **protease** inhibitors, 475–477  
 selective toxicity, 267
- HIV reverse transcriptase, 462–463
- HIV reverse transcriptase enzyme, 469
- HIV reverse transcriptase inhibitors, 465, 469–470  
 nonnucleoside reverse **transcriptase** inhibitors, 472–473  
 nucleoside reverse **transcriptase** inhibitors, 470–472
- HIV ribonuclease inhibitors, 465, 473
- HIV vaccines, 465
- HIV virion, 460  
 inhibitors of assembly, 474–475
- HIV virus, 458–459  
 assembly of viral proteins: virion formation, 464  
 binding to host cell membrane, 462  
 cellular picture of infection, 459–460  
 clinical picture of infection, 460  
 DNA entry to host cell nucleus, 463–464  
 DNA formation by reverse transcriptase, 462–463  
 fusion with host cell cytoplasm and its uncoating, 462  
 genome, 461  
 integration of viral DNA into host genome, 464  
 life cycle, 461–464  
 maturation, 464  
 migration of viral **mRNA** to cytoplasm, 464  
 mode of viral transmission, 459  
 splicing of viral **mRNA** into host genome, 464  
 structure and molecular biology, 460–461  
 targets for drug design, 464–477  
 viral budding out of host cell, 464
- HIV-1 virus, 459  
 and malaria, 930  
 vector for cancer gene therapy, 41
- HIV-2 virus, 459
- hMLH1**, 27, 32  
 hypermethylation, 9
- HMPA  
 for **poxviruses**, 341
- hMSH2**, 27, 32
- Hormone replacement therapies, 250–251
- HPMPA  
 for adenoviruses, 340  
 for polyomaviruses, 340
- hPMS1** gene, 27
- hPMS2** gene, 27
- H-ras protein, 22, 24  
 and **COX-2**, 34
- 5-HT, *See* Serotonin
- HTLV I (Human T Leukemia Virus I), 459
- HTLV II (Human T Leukemia virus II), 459
- HTLV III (Human T Leukemia Virus III: HIV virus), 459.  
*See also* HIV virus
- Human herpesvirus-8 virus, 296
- Humanized antibodies, 226  
 for organ transplant rejection, 509  
 selective toxicity, 257
- Human leukocyte antigens, 236–237
- Hybridomas, 226
- Hydrolapachol  
 antimalarial, 976
- Hydroxychloroquine**, 938  
 dosage forms, 934
- Hydroxylamine  
 radioprotective agent, 162
- Hydroxyl-containing compounds  
 radioprotective agents, 163
- 8-Hydroxyquinoline  
 radioprotective agent, 163
- Hydroxystreptomycin, 840
- 5-Hydroxytryptophan  
 radioprotective agent, 165
- Hydroxyurea  
 for herpes, 322  
 radiosensitizer, 195
- Hypoxanthine **aminopterin-thymidine**, 226
- Hypoxanthine phosphoribosyl transferase, 226
- Hypoxia  
 nitroimidazole binding for detection, 180  
 radioprotective agents utilizing, 154, 167–168
- Hypoxia-activated prodrugs, 83–87
- Hypoxia inducible factor-1 $\alpha$  and carcinogenesis, 20
- IAZGP**  
 radiosensitizer, 180
- Idarubicin**  
 antitumor natural product, 110, 124, 128
- Ifex**  
 alkylating agent, 54
- IFN- $\alpha$ , *See* Interferon- $\alpha$
- Ifosfamide  
 alkylating agent, 53, 54, 55
- Ile-2-AM (actinomycin C), 111
- Imatinib  
 selective toxicity, 257
- Imidacloprid  
 selective toxicity, 278
- Imipenem, 671  
 antimycobacterial application, 858  
 coadministration of cilastin, 623–624  
 discovery, 668–669  
 indications, 625  
 **$\beta$ -lactamase** classification  
 based on activity, 620, 621  
 MIC 90, 685  
**pharmacokinetics**, 624  
 side effects and interactions, 625  
 use recommendations, 626  
 in vitro activity, 692, 693  
 in *vivo* efficacy in systemic murine infections, 685
- Imipramine  
 radioprotective agent, 165
- Immortality, 10–11
- Immune system, 224–226
- Immunity, 224–226
- Immunodeficiency, 294
- Immunoglobulins  
 and adaptive immunity, 225, 227  
 RSV antiviral agents, 395
- Immunomodulation, 43–44  
 herpes virus antiviral agents, 325–326
- Immunosuppressive drugs, 486.  
*See also* Cyclosporine; **FK 506**; Organ transplant drugs
- Immunotherapy  
 antibody-directed, 226–235  
 anti-inflammatory therapeutic antibodies, 233–235

- chimeric antibodies, 226
- dendritic** cell, 235–243
- humanized antibodies, 226
- Immunotoxins, 92
- Imprinting
  - and carcinogenesis, 8
- Indinavir
  - anti-HIV drug, 475–476
- Indocin**
  - selective toxicity, 274
- Indomethacin
  - selective toxicity, 274
- Infliximab, **229, 233–234**
- Influenza A virus, 364
- Influenza B virus, 364
- Influenza hemagglutinin inhibitors, 377–384
- Influenza **M2** protein inhibitors, 388
- Influenza neuraminidase inhibitors, 364–377
- Influenza **RNA** transcriptase inhibitors, 384–388
- Influenza virus antiviral agents, 364
  - inhibitors of influenza **hemagglutinin**, 377–384
  - inhibitors of influenza **M2** protein, 388
  - inhibitors of influenza **neuraminidase**, 364–377
  - inhibitors of **RNA** transcriptase, 384–388
  - other inhibitors, 388–390
  - selective toxicity, 267
- Initiation, in carcinogenesis, 3–5
- Innate immunity, 224
- Insecticides
  - selective toxicity, 277–279
- Insulin
  - radiosensitizer, 194
- Insulin and hypoglycemic agents, 250–251
- Insulin-like growth factor 1
  - radiosensitizer, 194
- Integrase, 616
- Integrins, 13
- Integrins
  - and  **$\beta$ -lactam** resistance, 614–616
- Intercalation, 67
- Interferon- $\alpha$** 
  - for hepatitis B virus, 326, 334
  - for hepatitis C virus, 361, 362–364
  - for papillomavirus, 337–338
  - radioprotective agents, 171
- Interferon  $\gamma$ 
  - and adaptive immunity, 225
- Interleukin-1
  - radioprotective agent, 171
- Interleukin-2**
  - and adaptive immunity, 225
- Interleukin-4**
  - and adaptive immunity, 225
  - radioprotective agent, 171
- Interleukin-5**
  - and adaptive immunity, 225
- Interleukin-6**
  - and adaptive immunity, 225
  - radioprotective agent, 171
- Interleukin-10
  - and adaptive immunity, 225, 226
- Internal ribosome entry signal, 41
- Interstitial collagenase, 13
- Intestine transplantation, 487
- Int-2 growth factor, 22
- Intoplicine
  - dual topoisomerase **I/II** inhibitor, 68, 73, 74
- Intraepithelial neoplasia, 35
- Intratransguanylation, 158
- Invadopodia, 13
- Iodine topical antibacterials, 547
- 5-Iododeoxyuridine
  - radiosensitizer, 194
- Ionizing radiation. See also Radioprotective agents
  - and carcinogenesis, 4, 33
  - damage from, 153–154
  - p53** activation, 28
- Iproniazid, 834
- Iressa**, 12
- Irinotecan
  - antitumor natural product, 110, 131
- Isoartemisitenone, 965
- Isobombycol
  - radioprotective agent, 167
- Isofebrifugine**
  - antimalarial, 998
- Isoniazid, 833–834
  - activity and mechanism of action, 834–835
  - drug interactions, 862, 864
  - efficacy and dosage, 810, 863
  - selective toxicity, 266
  - side effects, 835
- Isopodophyllotoxins
  - antitumor natural products, 110, 134–136
- Isosulfazecin, 664
- Isothiazoles
  - picornavirus antiviral agents, 403
- Isoxyl**, 810
- Itraconazole, 893–897
  - formulations and indications, 890, 891
  - selective toxicity, 268
- Ivermectin
  - antihelmintic, 1091, 1093–1094
- J-111, 225, 682, 684, 708
  - in vivo efficacy in systemic murine infections, 685
- J-111**, 347, 682, 683, 684
- J-114**, 870, 682, 684, 685
- J-114, 871, 683, 684, 685
- Japanese encephalitis virus, 427, 429–430
- JM-83
  - alkylating agent, 54
- JM-216
  - alkylating agent, 54, 60
- JM-473
  - alkylating agent, 60
- Josamycin, 763
- Jun protein, **22, 25**
- Kalihinol A
  - antimalarial, **993–994**
- Kanamycin
  - antimycobacterial application, 811, 842–844
  - efficacy and dosage, 811, 863
  - selective toxicity, 260–261
  - side effects, 844
- Kanamycin A, 842–843
- Kanamycin B, 842–843
- Kanamycin C, 842–843
- Kantrex**, 811
- Kaposi's sarcoma, 299
- Ketoconazole, 893–897
  - formulations and indications, 890, 891
  - selective toxicity, 268
- Ketolides, 776–781
- Kidney transplantation, 487, 489
  - 1-year survival rate, 488
- KIN-802
  - radiosensitizer, 179
- KIN-804
  - radiosensitizer, 179
- Kinase tumor-activated **prodrugs**, 90

- Kinetoplastid parasitic diseases, 1035  
 antiprotozoal agents for, 1035–1076
- KM231-DU257**  
 tumor-activated prodrug, 83, 94
- Korundamine A**  
 antimalarial, 995,996
- Korupensamines**  
 antimalarial, 995,996
- KP-736**, 643, 646
- K-ras protein**, 22, 24  
 and **COX-2**, 34
- KRM-1648**,847,852
- KU-2285**  
 radiosensitizer, 180
- KW-2189**  
 alkylating agent, 54, 61, 64
- L-696**,256, 703, 706
- L-708**,906  
 anti-HIV drug, 473,474
- L-731**,988  
 anti-HIV drug, 473,474
- L-741**,462, 703, 706
- L-742**,728, 703, 706, 707
- L-786**,392, 703, 705, 706, 707
- L-793**,422,908
- $\beta$ -Lactam antibiotics**, 608–610.  
*See also* specific antibiotics and classes of antibiotics, such as Cephalosporins or Penicillins  
 antibacterial broad-spectrum, 705–709  
 antimycobacterials, 858  
 clinical application, 623–628  
 combination therapies, 625, 626  
 current trends driving industry, 711–714  
 discovery, 628–637  
 hydrolysis, 609, 619–621  
 mechanism of action, 610–613  
 mechanism of resistance to, 613–623  
 mosaic gene formation, 616–618  
 recent developments, 701–711  
 selective toxicity, 254,260  
 side effects and interactions, 624–625
- $\beta$ -Lactamase inhibitors**  
 antimycobacterials, 858  
 classification, 694–701  
 development of, 609  
 recent developments, 710–711
- $\beta$ -Lactamases**, 608–609  
 classification and relevance in clinics, 618–621  
 evolution, 618  
 extended-spectrum, 619  
 molecular and phenotypic classification, 620
- $\beta$ -Lactamase tumor-activated prodrugs**, 88
- Lamiazid**, 810
- Laminin**, 12,216
- Lamisil**, 890, 891
- Lamivudine**  
 anti-HIV drug, 471,472  
 drug resistance, 333–334  
 for hepatitis B virus, 327–329, 335–336  
 selective toxicity, 267
- Lamprene**, 810
- Langerhans cells**, 224
- Lanvis**  
 antimetabolite. 76
- Lapinone**  
 antimalarial, 976
- Lapudrine**, 959
- Lariam**, 934
- Latamoxef**, 652
- Lck tyrosine kinase**, 22
- Leflunomide**, 489  
 clinical use for organ transplants, 522–523  
 side effects, 523
- Leishmaniasis**  
 antiprotozoal agents for, 1035, 1047–1052
- Lenampicillin**, 632
- Lentiviruses**  
 vectors for cancer gene therapy, 41
- Leprosy**, 809–813,1035  
 pathogenesis and epidemiology, 825–826  
 recent developments and present status of chemotherapy, 865–866
- Leucovorin**  
 with irinotecan, 131
- Leukeran**  
 alkylating agent, 54
- Leukotrienes**  
 radioprotective agent, 171–172
- Levamisole**  
 selective toxicity, 273
- Levobupivacaine**  
 selective toxicity, 273
- Levofloxacin**, 853
- Levopropoxyphene**  
 selective toxicity, 269–270
- Levothyroxine**, 250–251
- L-FMAU**  
 for hepatitis B virus, 327, 329–330
- Licochalcone A**  
 antimalarial, 999
- Lincomycin**, 787–788
- Lincosamides**, 787–789
- Linezolid**, 792–793  
 systemic antibacterial, 588–590
- Lipophilic antifolates**, 79
- Lipoplex**  
 for nonviral gene delivery, 42–43
- Liposomes**  
 with influenza antivirals, 382  
 with vincristine, 142
- Liver transplantation**, 487
- LJC-084**, 709–710
- LJC-11036**, 709
- Lobucivar**  
 for hepatitis B virus, 333
- Loceryl**, 891
- Lomefloxacin**, 853
- Lomustine**  
 alkylating agent, 54, 64–65
- Lopinavir**  
 anti-HIV drug, 476–477  
 selective toxicity, 267
- Loprox**, 891
- Loracarbef**, 654
- Loratidine**  
 selective toxicity, 275
- Losoxantrone**  
 topoisomerase II inhibitor, 68, 72
- L1210** screening, for antitumor agents, 109
- Lumefantrine**  
 antimalarial, 978–979  
 dosage forms, 935
- Lung transplantation**, 487
- Lurotecan**  
 antitumor natural product, 133
- LY-303366**,902
- LY-338387**  
 picornavirus antiviral, 407
- LY-343814**  
 picornavirus antiviral, 409–410



- LY-353349**  
 picornavirus antiviral, 409  
**LY-353352**  
 picornavirus antiviral, 409  
**LY-466700**  
 hepatitis C antiviral, 416  
 Lymphadenopathy associated virus (**LAV/HIV-2**), 459  
 Lymphatic filariasis, 1035  
 Lysozyme, 224  
  
**M-8506**, 953  
**M-14659**, 643  
 Macrolide antibiotics. See also Erythromycins  
 antimycobacterials, 855–858  
 biosynthesis, 765–774  
 4"-carbamate, 782  
 clinical use and currently used drugs, 758–761  
 drug resistance, 774–776  
 future developments, 784–785  
 nonbacterial activity, 782–784  
 pharmacology and mode of action, 762–765  
 recent developments, 776–782  
 selective toxicity, 261–263  
 side effects, toxicity, and contraindications, 761–762  
 structure-activity relationships, 765–774  
 Macrophages  
 and adaptive immunity, 225, 227  
 and innate immunity, 224  
 Major histocompatibility complex proteins, 224–225, 235  
 and organ transplant rejection, 487  
 and peptide immunogenicity, 238–239  
 Malaria, 920–921, 1035. See also Antimalarial agents  
 economic and political issues, 932–933  
 global incidence, 926–928  
 immunity and prophylaxis, 930–932  
 Malaria parasites, 921–924  
 biochemistry and genetics, 924–926  
 vector control, 931–932  
 Malaridine, 979  
 Malarone, 935  
 antimalarial, 976–978  
 (+)-Malekulatine  
 antimalarial, 997  
  
 Maloprim, 934  
 L-Mannaric acid  
 anti-HIV drug, 476–477  
 Mannosidostreptomycin, 840  
 Manzamine A  
 antimalarial, 994  
 Mappia foetida, 130  
 Marboran  
 smallpox antiviral agent, 435, 437  
 Marcellomycin  
 antitumor natural product, 124, 126  
 Marimastat, 217, 218  
 Matrilysin, 13, 14  
 Matrix metalloproteinase inhibitors  
 antiangiogenic agents, 216–217  
 for cancer, 45–46  
 for cancer treatment, 37–38, 45  
 Matrix metalloproteinases  
 and angiogenesis, 216  
 and carcinogenesis, 12–14  
 Maximum tolerated dose (**MTD**), 154  
 May apple, drugs derived from, 134  
**MC-02331**, 703, 704  
**MC-02363**, 703, 704  
**MC-02479**, 703, 704  
**MC-510**, 027, 909, 910  
 Mdm2 gene  
 and p53 gene, 29  
 Measles virus, 390  
 antiviral agents, 390–396  
 Mebendazole  
 antihelmintic, 1090–1091, 1091  
 Mechlorethamine  
 alkylating agent, 53, 54, 55  
 Mecillinam, 633–634  
 in *vitro* antibacterial activity, 635  
 Mefloquine  
 antimalarial, 943–946  
 dosage forms, 934  
 Meglumine  
 for leishmaniasis, 1049–1051  
 Melarsoprol  
 for African trypanosomiasis, 1041–1043  
 Mellein  
 hepatitis C antiviral, 422, 424  
 Melphalan  
 alkylating agent, 53, 54  
  
**MEN1** gene, 27  
 Menoctone  
 antimalarial, 976  
**Mentax**, 891  
 Mephaquine, 934  
 Mepron, 935  
 2-Mercaptoethylamine (**MEA**)  
 radioprotective agent, 152, 155–160, 169–170, 172  
 2-Mercaptoethylguanidine (**MEG**)  
 radioprotective agent, 158–160, 161  
 2-Mercaptopropylguanidine (**MPG**)  
 radioprotective agent, 158, 161  
 6-Mercaptopurine, 513  
 antimetabolite, 75, 76, 81  
 resistance to, 290  
 2-Mercaptothiolazine  
 radioprotective agent, 160  
 Mercury compounds  
 topical antibacterials, 552553  
 Meropenem  
 antimycobacterial application, 858  
 discovery, 668–669, 680–681  
 pharmacokinetics, 623–624  
 side effects and interactions, 625  
 use recommendations, 626  
 in *vitro* activity, 692  
 Merozoites, 920, 922  
 Mesna  
 radioprotective agent, 172  
 Messenger RNA, See mRNA  
 Metabolic inhibitors  
 radioprotective agents, 162–163  
 radiosensitizers, 193–196  
 Metal ion complexes  
 radioprotective agents, 163  
 radiosensitizers, 196  
 Metalloelastase, 13  
 Metastasis, 12  
 Methenamine  
 systemic antibacterial, 596  
 Methicillin, 631  
 in *vitro* antibacterial activity, 635  
 Methicillin-resistant staphylococci, 617–618  
 Methisazone  
 activity against orthopoxviruses, 439  
 smallpox antiviral agent, 435, 437

- Methotrexate  
 antimetabolite, 75, 76, 77, 78–79  
 flavivirus antiviral, 428  
 with **infliximab**, 234  
 selective toxicity, 264
- Methylating agents, 54
- Methylation, See DNA **hyper-methylation**; DNA **methylation**
- 1 $\beta$ -Methylcarbapenems**, 675–683
- Methyl-CpG-binding **domain**-containing proteins, 8
- Methylene blue  
 antimalarial, 988
- 1-Methyl-3-nitro-1-nitrosourea  
 alkylating agent, 64
- 2-Methylpiperazinedithioformate**  
 radioprotective agent, 160–161
- Meticillin, 609
- Metronidazole  
 radiosensitizer, 178
- Mezlocillin, 633  
 indications, 625  
**pharmacokinetics**, 624
- Micafungin, 888, 901, 903
- Micatin**, 891
- Miconazole, 893–897  
 formulations and indications, 891  
 selective toxicity, 268
- Microtubules, 136
- Midecamycin**, 763
- Miltefosine  
 for leishmaniasis, 1051–1052
- Minocin, 740
- Minocycline**, 740, 742
- Miokamycin, 763
- Mismatch repair genes, 8  
 and cancer heritable syndromes, 32
- Misonidazole, 84  
 radiosensitizer, 177
- Mithracin  
 antitumor natural product, 122–124
- Mithramycin  
 antitumor natural product, 110, 122–124
- Mitogen-activated protein **kinases**  
 and carcinogenesis, 24
- Mitomycin A  
 antitumor natural product, 120, 121
- Mitomycin C  
 antitumor natural product, 120–122  
 hypoxic selectivity, 84–85  
 radiosensitizer, 182
- Mitomycins  
 antitumor natural product, 110, 120–122  
 tumor-activated **prodrug**, 87
- Mitosis promoting factor, 193
- Mitoxantrone, 85  
 topoisomerase II inhibitor, 68, 69, 70–71
- Mitozolomide**  
 alkylating agent, 54, 65, 66–67
- Mixed disulfide hypothesis, of radioprotective agents, 168–169
- Mizoribine, 489  
 clinical use for organ transplants, 521–522  
 side effects, 522
- MK-0787, 668–669
- MK-826, 682, 684, 708
- MM-4550, 670  
 activity, 690
- MM-13902, 670  
 activity, 690  
 in vitro activity, 692
- MM-17880, 670
- MM-22380, 670
- MM-22381, 670, 675
- MM-22382, 670
- MM-22383, 670, 674
- mob genes, 614
- Monistat, 891
- Monobactams, 664–668  
 brief description, 609  
 use recommendations, 626
- Monoclonal antibodies. See also Humanized antibodies  
 anti-HIV drug, 475–476  
 clinical use for organ transplants, 489, 509–513, 525–526  
**pharmacokinetics**, 510  
 pharmacology, 510–513  
 selective toxicity, 257  
 side effects, 513
- Montelukast sodium (**MK-0476**)  
 selective toxicity, 252
- Morphazinamide, 836
- Morpholine antifungal agents, 903
- Mort1, 17
- Mosaic genes, 616–618
- Mos protein **kinase**, 22
- Moxalactam, 652–653
- Mozenavir  
 anti-HIV drug, 476–477
- MRL-1237  
**picornavirus** antiviral, 413
- mRNA**  
 bacterial, 738
- Mucor**, 883
- Mucormycosis, 883
- Multidrug resistance proteins, 285–286
- Multidrug resistance-related protein, 285–286
- Murine leukemia virus  
 vectors for cancer gene therapy, 41
- Muromonab **CD3**, 490
- Musettamycin  
 antitumor natural product, 124, 126
- Mustards, See Nitrogen mustards
- Mustargen**  
 alkylating agent, 54
- Mutamycin  
 antitumor natural product, 120–122
- Mutated in multiple advanced cancers (**MMAC**) tumor **suppressor** gene, 30
- Mutation  
 ionizing radiation, 153–154  
 and tumorigenesis, 2
- Mutation hot spots, 5
- Myambutol, 810
- Mycobacteria, 813–821. See also Antimycobacterial agents  
 pathogenesis and epidemiology, 821–826
- Mycobacteria other than tuberculosis, 814, 824
- Mycobacterium, 813–814
- Mycobacterium abscessus, 815  
 regimen for treatment, 867
- Mycobacterium africanum, 814
- Mycobacterium avium, 809, 814, 815  
 regimen for treatment, 866
- Mycobacterium *bovis*, 813, 814, 815, 820–821, 823
- Mycobacterium *chelonae*, 815
- Mycobacterium *fortuitum*, 815  
 regimen for treatment, 867

- Mycobacterium *haemophilum*, 815  
 Mycobacterium *kansasii*, 815  
   regimen for treatment, 866  
 Mycobacterium *leprae*, 809,  
   825–826  
   susceptibility testing, 827  
 Mycobacterium *malmoense*, 815  
   regimen for treatment, 866  
 Mycobacterium *marinum*, 815  
   regimen for treatment, 866  
 Mycobacterium *microti*, 814  
 Mycobacterium *scrofulaceum*,  
   815  
   regimen for treatment, 866  
 Mycobacterium *simiae*  
   regimen for treatment, 866  
 Mycobacterium tuberculosis, 809,  
   813–825  
   susceptibility testing,  
   826–829  
 Mycobacterium *ulcerans*, 815  
 Mycobacterium *xenopi*, 815  
 Mycobactin M, 818  
 Mycobactin P, 818  
 Mycobactin S, 818  
 Mycobutin, 811  
**Mycolic acid**, 816  
 Mycophenolate mofetil, 489,490  
   clinical use for organ trans-  
   plant~518–521  
   for herpes, 321–322  
   with leflunomide, 523  
   side effects, 521  
   structure-activity relationship,  
   520–521  
 Mycophenolic acid, 518  
   flavivirus antiviral, 428  
   for herpes virus, 321  
 Myc protein, 22, 25–26  
 Mylotarg, 228,231  
   tumor-activated **prodrug**, 83,  
   92  
**N-Myristoyl** transferase inhibi-  
   tors, 908–909,910  
**M1 zinc finger peptides**  
   influenza antiviral agents, 387  
 Nafcillin, 631  
   biliary excretion, 623  
   **pharmacokinetics**, 624  
 Naftifine, 899–900  
   formulations and indications,  
   891  
 Naftin, 891  
 Naked **plasmid** DNA  
   for cancer therapy, 39  
 National Cancer Institute data-  
   base  
   antitumor natural products,  
   110  
 Natural **killer** cells, 225  
 Natural products. See also Anti-  
   tumor natural products  
   antimalarial agents, 993–999  
 Navelbine  
   antitumor natural product,  
   142–143  
 Neem, 996  
**Neflavinir**  
   anti-HN drug, 475–476  
 Neisseria  
   penicillin-binding protein,  
   614,616,617  
 Nelfinavir  
   selective toxicity, 267  
 Neohesperidin  
   **rotavirus** antiviral, 431  
 Neomycin, 748  
   selective toxicity, 260–261  
 Neonicotinoids  
   selective toxicity, 278  
 Neoral, 491,492  
 Neosporin, 748  
 Netilmicin, 748  
 Neutral red  
   hepatitis C antiviral, 417  
**NeuTrexin**  
   antimetabolite, 76  
 Neutrophils  
   and adaptive immunity, 225,  
   227  
   and innate immunity, 224  
 Nevirapine  
   anti-HN drug, 472  
   selective toxicity, 267  
**NF1** gene, 27  
 Nicotinamide  
   radiosensitizer, 184  
 Niftifine  
   selective toxicity, 268  
 Nifurtimox  
   for American trypanosomiasis  
   (**Chagas'** disease),  
   1046–1047  
 Nigericin  
   antimalarial, 991  
 Nikkomycins, 906  
 Nimorazole  
   radiosensitizer, 178–179  
 Nitidine  
   dual topoisomerase I/II inhibi-  
   tor, 73  
 Nitracine  
   radiosensitizer, 179–180  
 Nitracine N-oxide, 84, 85–86  
**Nitriles**  
   radioprotective agent,  
   162–163  
 Nitrioltriacetate  
   radioprotective agent, 163  
 Nitrobenzamide  
   anti-HN drug, 469,470  
 9-Nitrocamptothecin  
   antitumor natural product, 133  
 Nitrofurans  
   systemic antibacterial,  
   594–596  
 Nitrogen mustards  
   alkylating agents, 52, 53–57  
   minor groove targeting, 57–59  
 Nitroimidazoles  
   binding to hypoxic cells,  
   180–182  
   radiosensitizers, 177  
 Nitroimidazopyrans  
   antimycobacterial application,  
   858–859  
**N-Nitroso-N-phenylhydroxy-**  
   **lamine**  
   radioprotective agent, 163  
 Nitrosureas  
   alkylating agents, 54, 64–65  
 Nitroxides  
   radioprotective agent, 171  
 Nivaquin, 934  
 Nizoral, 890,891  
 NK 109  
   dual topoisomerase I/II inhibi-  
   tor, 73  
 NLP-1  
   radiosensitizer, 179  
**NMSO3**, 394  
 Nocardicin A, 660,661,663–664  
 Nocardicin B, 661,663  
 Nocardicin C, 660,661, 663  
 Nocardicin D, 661, 663  
 Nocardicin E, 661, 663  
 Nocardicin F, 661,663  
 Nocardicin G, 663  
**Nocardicins**  
   biological activity, 663–664  
   synthesis, 660–663  
 Nolatrexed  
   antimetabolite, 76, 79  
 Nolvadex  
   selective toxicity, 276  
 Nonnucleoside HIV reverse  
   transcriptase inhibitors,  
   472–473

- Nonreceptor **tyrosine kinases**, 24–25
- Nonsteroidal anti-inflammatory **drugs**  
and decreased cancer risk, 34
- Nontuberculosis mycobacteria, 814,824
- Norfloxacin**  
antimalarial, 936,983
- Novantrone  
topoisomerase II inhibitor, 68
- Novrad**  
selective toxicity, 269–270
- NP-27,891
- N-ras protein, **22, 24**
- NSC 356894,490
- Nucleoside HIV reverse **tran-**  
scriptase inhibitors,  
470–472
- Nydravid**, 810
- Nystatin, 889,893  
formulations and indications,  
891
- OCA-983,709
- Ofloxacin, 853–855
- Old tuberculin, 818–819
- Oligonucleotide therapeutics  
RSV antiviral agents, 396–397
- Omaciclovir  
for herpes virus, 310
- Omeprazole  
antimalarial, 989  
with quinine, 936
- Onchocerciasis, 1035
- Oncogenes, **3, 21–26**  
targeting loss of function,  
44–45  
transcription factors as, 25–26  
types of, 22
- Oncovin  
antitumor natural product,  
142
- OPTCOL method, 381
- Organ transplantation, 486–487  
recent developments, **523–526**  
trends in management of,  
487–489
- Organ transplant **drugs**  
agents **blocking** nucleotide  
synthesis, **513–523**  
agents blocking T-cell func-  
tion, **489–513**  
clinical use, 489  
recent developments, **523–526**
- Organ transplant rejection,  
486–487  
t-cell's role in, 487–488
- Ormaplatin  
alkylating agent, **54, 59**
- Ornithine **decarboxylase**  
genetic variability in expres-  
sion, 7
- Orthopoxviruses**, 435–437  
antiviral agents, 435–440
- Oseltamivir, 361  
for **influenza**, 368–372  
selective toxicity, 266,267
- Osteoporosis, 273
- Oxacephalosporins, 652–654
- 1-Ox-acephalothin**, 652
- Oxacephems, 652–654  
brief description, 609
- Oxacillin, 631  
biliary excretion, 623  
 **$\beta$ -lactamase** classification  
based on activity, 619,620,  
621  
**pharmacokinetics**, 624
- 1-Oxadethiacephems**, 652–654
- Oxaliplatin  
alkylating agent, **54, 59–60,**  
61
- Oxamniquine  
antihelmintic, 1091, 1095
- Oxapenams  
brief description, 609
- Oxazolidinones, 792–793  
antimycobacterial application,  
859  
systemic antibacterials,  
**587–594**
- Oxiconazole, 904  
formulations and indications,  
891
- Oxidase tumor-activated **pro-**  
drugs, 91
- Oxidizing agents  
topical antibacterials, **551–552**
- Oximonam, 666,668  
in *vitro* activity, 667
- Oxistat**, 891
- Oxytetracycline**, 740, 742
- p53** gene, 27–29  
and drug resistance, 287–289  
gene therapy target, 44–45  
role in cell cycle, 16
- PA-505  
antimycobacterial, 859
- PA-824  
antimycobacterial, 859
- Pacific yew, **paclitaxel** from, 136
- Paclitaxel  
antitumor natural product,  
110,136–138  
with **RSR13**, **190**  
selective toxicity of antibody  
conjugate, 258  
with tirapazamine, 85
- Palivizumab**, 227,395
- Paludrine, 934
- Paluther, 935
- Pamaquine, 950
- Pancreas transplantatio'n, 487  
1-year survival rate, 488
- Panipenem, 677,693
- Papillomaviruses, 297,301–302  
antiviral agents, 337–339
- Paracoccidioides brasiliensis,  
883
- Paracoccidioidomycosis, 883
- Parainfluenza virus, 390  
antiviral agents, **390–398**
- Paramyxovirus fusion proteins  
antiviral agents, **390–396**
- Paraplatin  
alkylating agent, 54
- Parasitic infections, 1035, 1090.  
See also Malaria
- Paromomycin  
for leishmaniasis, 1051
- Parvoviruses, **304–305**  
antiviral agents, **341–342**
- Paser, 810
- Pefloxacin  
antimalarial, 983
- Pegasys, 363
- Pegylated agents, See Polyethyl-  
ene glycol (PEG)
- Penams, 609  
 **$\beta$ -lactamase** inhibitors,  
698–699
- Penam** sulfones  
 **$\beta$ -lactamase** inhibitors,  
698–699
- Penciclovir  
for hepatitis B virus, 330–331,  
334  
for herpes virus, 307–308
- Penems, 609  
 **$\beta$ -lactamase** inhibitors,  
698–699  
synthesis, 654–659
- Penicillinase-resistant** penicillins  
use recommendations, 626
- Penicillin-binding proteins, 613  
evolution, 618

- modification of native,  
616–618  
and resistance to  $\beta$ -lactams,  
613–616
- Penicillin dihydro F, 629
- Penicillin F, 629
- Penicillin G, 608,609,631. *See*  
*also* Benzylpenicillin  
**pharmacokinetics**, 624  
structure, 628,629  
use recommendations, 626  
*in vitro* antibacterial activity,  
635,667
- Penicillin K, 629
- Penicillin N, 629
- Penicillin *iso-N*, 629
- Penicillin *O*, 629
- Penicillins  
antimycobacterial application,  
858  
brief description, 609  
discovery of, 628–637  
 $\beta$ -lactamase classification  
based on activity, 620,621  
**pharmacokinetics**, 623  
selective toxicity, 253–254,  
260  
side effects and interactions,  
624–625  
synthesis, 629–630
- Penicillin sulfoxide-cephalo-  
sporin conversion, 646–649
- Penicillin T, 629
- Penicillin V, 608,609,629, 631
- Penicillin X, 629
- Penicillium*, 608
- Penicillium chrysogenum*, 609,  
628
- Penicillium notatum*, 628
- Pentafuside**  
anti-HIV drug, 468–469
- Pentamidine  
for African trypanosomiasis,  
1037–1039  
for leishmaniasis, 1051–1052
- Pentostatin  
antimetabolite, 76, 81
- Pentoxifylline**  
radiosensitizer, 184
- Pepleomycins  
antitumor natural products,  
115
- Peptidase tumor-activated pro-  
drugs, 87–88
- Peptides**  
RSV antiviral agents, 395–396
- Peptidoglycan, 610–612
- Peptidoglycan transglycosylases,  
610
- Peramivir**, 374376
- Pericytes**, 216
- Permetrexed  
antimetabolite, 76, 78
- Pestivirus, 427
- Phenethicillin, 631
- Phenols  
topical antibacterials, 548–550
- Phenytoin  
with bleomycin, 116
- Phialophora*, 883
- Philadelphia chromosome, 19
- Phleomycins  
antitumor natural products,  
115,117
- Phosphatase and **tensin homo-  
logue (PTEN)** tumor sup-  
pressor gene, 30
- Phosphatase tumor-activated  
**prodrugs**, 87
- Phosphodiesterase inhibitors  
selective toxicity, 277
- Phosphoinositol 3-kinase, 24
- Photodynamic therapy,  
174–175
- Photofrin, 174–175
- Phthalocyanines  
**radiosensitizers**, 175
- Phthisis, 809–810
- Phthivazid, 834
- Picornaviral protein 2C inhibi-  
tors, 413
- Picornaviruse **protease** inhibi-  
tors  
nonpeptidic, 409–411  
peptidic, 404–409
- Picornaviruses, 398  
antiviral agents, 398–415
- Picovir**  
**picornavirus** antiviral,  
399–400
- Picropodophyllotoxin  
antitumor natural product,  
134
- Pimonidazole  
radiosensitizer, 179, 180
- Piperacillin**, 609,633  
antimycobacterial application,  
858  
indications, 625  
**pharmacokinetics**, 624  
use recommendations, 626  
*in vitro* antibacterial activity,  
635
- Piperaquine  
antimalarial, 990
- Piperazine  
antihelmintic, 1091, 1095
- Piritrexim**  
antimetabolite, 76, 79
- Pirodavir  
**picornavirus** antiviral, 400–401
- Piroxantrone  
topoisomerase II inhibitor, 68,  
72
- Pivarnpicillin, 632
- Plaquenil, 934
- Plasmid DNA-mediated gene  
therapy**  
for cancer, 39–40
- Plasmids**  
and  $\beta$ -lactam resistance,  
614–616
- Plasminogen activator inhibi-  
tor-1  
for angiogenesis control, 45
- Plasmodium berghei*, 923
- Plasmodium brasilianum*, 921
- Plasmodium cynomolgi*, 923
- Plasmodium falciparum*, 920  
biochemistry and genetics,  
924–926  
drug resistance, 928–930  
global distribution, 927  
life cycle, 921–924
- Plasmodium fragile*, 921
- Plasmodium knowlesi*, 923
- Plasmodium malariae*, 920  
life cycle, 921–924
- Plasmodium ovale*, 920  
life cycle, 921–924
- Plasmodium simiovale*, 921
- Plasmodium vinckei*, 923
- Plasmodium vivax*, 920  
biochemistry and genetics,  
924  
drug resistance, 928–930  
global distribution, 927  
life cycle, 921–924
- Plasmodium yoelii*, 923
- Plasmotrim, 935
- Platelet-derived growth factor,  
217–218
- Platelet-derived growth factor  
inhibitors  
**antiangiogenic** agents,  
218–219
- Platelets  
exosome secretion, 241

- Platinum complex alkylating agents, 54, 59–61. See also Cisplatin
- Platamycins  
antitumor natural products, 117
- Pleconaril  
picornavirus antiviral, 399–400
- Plicamycin  
antitumor natural product, 110, 122–124
- Pluracidomycin A, 670, 671  
in vitro activity, 692
- Plymecillin, 609
- Pneumocystis carinii*, 460, 883
- Pneumocystosis, 883
- Podophyllin  
for papillomavirus, 338
- Podophyllotoxins  
alkylating agents, 52  
antitumor natural product, 134
- Podophyllum peltatum (May apple), 134
- Polycyclic carbapenems, 683–688
- Polyene antifungal agents, 889–893, 890, 891
- Polyethylene glycol (PEG)  
with interferon- $\alpha$  for hepatitis C, 363–364
- Polymerase chain reaction  
with mycobacteria, 826
- Polymeric radioprotective agents, 166–167
- Polyomaviruses, 302–303  
antiviral agents, 339–340
- Polyoxins, 906
- Polyoxometalates  
broad spectrum antiviral agents, 435
- Polyplex  
for nonviral gene delivery, 42
- Polyvinyl alcohol sulfate  
anti-HIV drug, 466
- Porfimer sodium, 174–175
- Porfiromycin  
tumor-activated prodrug, 83, 85, 86
- Porphiromycin  
antitumor natural product, 120
- Posaconazole, 898–899
- Potentially lethal damage repair, 191–192
- Pott's disease, 809
- Poxviruses, 305  
antiviral agents, 340–341  
dendritic cell transduction by, 242–243
- Pradimicins, 908
- Praziquantel  
antihelmintic, 1091, 1093–1094
- Preincubation effect, radiosensitizers, 180
- Primaquine  
antimalarial, 949–954  
dosage forms, 934
- Primaxin, 693
- PRO440**  
anti-HIV drug, 468
- Probenecid  
with cephalosporins, 623
- Procaine  
radioprotective agent, 166
- Procaspase-8  
and apoptosis, 17
- Procaspase-9  
and apoptosis, 18–19
- Proflavine, 67
- Prograf**, 495
- Progression, in carcinogenesis, 3–5
- Progressive multifocal leukoencephalopathy, 302–303
- Proguanil  
antimalarial, 936, 954–956  
with dapsone, 959  
dosage forms, 934
- Promotion, in carcinogenesis, 3–5
- Propicillin, 609, 631
- Propoxyphene  
selective toxicity, 269–270
- Prostacyclin  
for cancer treatment, 38
- Prostaglandin H synthase 1, See COX-1
- Prostaglandin H synthase 2, See COX-2
- Prostaglandins  
broad spectrum antiviral agents, 432–435
- Protein swapping, 259
- Proteoglycans, 12
- Proteolysis  
inhibitors of, 216–217
- Prothionamide, 836  
efficacy and dosage, 810, 863
- Protooncogenes, 45
- Provirus, 463
- PS-5, 670, 671, 675  
in vitro activity, 692
- PS-6, 670, 671
- PS-15  
antimalarial, 960
- PS-26  
antimalarial, 960
- PS-33  
antimalarial, 960
- P388 screening, for antitumor agents, 109
- Pseudoallescheria boydii, 883
- Pseudoallescheriasis, 883
- Pseudomonas aeruginosa  
intrinsic resistance to  $\beta$ -lactams, 621–623  
 $\beta$ -lactams active against, 632–633
- Psilocybine, 165
- Purine analog antimetabolites, 76, 81–82
- Purine derivatives  
HBV virus antiviral agents, 330–333  
RSV antiviral agents, 389
- Purinethol  
antimetabolite, 76
- Purpurins**  
radiosensitizers, 175
- Pyrantel  
antihelmintic, 1091, 1094–1095
- Pyrazinamide**, 836–837  
drug interactions, 864  
efficacy and dosage, 810, 863  
side effects, 837
- Pyrimethamine  
antimalarial, 936, 956–957  
with dapsone, 959  
dosage forms, 934  
selective toxicity, 254, 264  
with sulfadoxine, 958–959  
useful lifetime before resistance develops, 930
- Pyrimidine analog antimetabolites, 76, 79–81
- Pyrimidine derivatives  
HBV virus antiviral agents, 326330  
influenza antiviral agents, 389  
RSV antiviral agents, 389
- Pyrimidines  
halogenated, as radiosensitizers, 194–195
- Pyronaridine  
antimalarial, 979–981  
dosage forms, 935

- Pyrrolidine-based** influenza inhibitors, 376–377
- Pyrrromycin**  
antitumor natural product, 124, 126, 130
- Qinghaosu (artemisinin)**, 961
- Quinacrine**, 979
- Quinamm**, 934
- Quinidine**  
antimalarial, 933–938  
dosage forms, 934
- Quinimax**, 933, 936–937
- Quinine**  
antimalarial, 933–938  
dosage forms, 934
- Quinocide**, 950
- Quinolones**  
selective toxicity, 263  
systemic antibacterials, 582–587
- Quinones**  
radiosensitizers, 177
- R-95867**, 709, 710
- R-170591**, 393–394
- Radiation damage**, 153–154
- Radiation therapy**. *See also* **Radioprotective agents**  
radioprotective agents in, 172–173
- Radioprotective agents**, 151–153  
antiradiation testing, 154  
biochemical shock, 169  
DNA breakdown control, 169–170  
free-radical process inhibition, 168  
heterocyclic compounds, 163–165  
hydroxyl-containing compounds, 163  
metabolic effects, 170–172  
metabolic inhibitors, 162–163  
metabolites and naturally occurring compounds, 166  
metal ion containing agents, 163  
miscellaneous substances, 166–167  
mixed disulfide hypothesis, 168–169  
physiologically active substances, 165–166  
polymeric substances, 166–167  
protection by **anoxia/hypoxia**, 154, 167–168  
sulfur-containing compounds, 160–162  
thiols and thiol derivatives, 152, 155–160  
use in radiotherapy and cancer chemotherapy, 172–173
- Radiosensitizers**, 173  
alteration of energy absorption, 173–175  
alteration of oxygen delivery, 183–190  
alteration of primary **radiolytic** products, 175–176  
bacterial sensitizers, 197  
for boron neutron capture therapy, 173–174  
depletion of endogenous protectors, 190–191  
**electron-affinic drugs** in cancer therapy, 180–183  
and hypoxia-activated **pro-drugs**, 83  
inhibition of DNA repair, 191–193  
metal ion complexes, 196  
perturbation of cellular metabolism, 193–196  
for photodynamic therapy, 174–175  
reaction with DNA radicals, 176–180  
thiols, 196–197  
unknown mechanism agents, 196–197
- Raf protein kinase**, 22, 24
- Raloxifene**  
selective toxicity, 276
- Raltitrexed**  
antimetabolite, 76, 77–78
- RANTES ligand**  
and **CCR5**, 467
- Rapamune**, 500, 503
- Rapamycin**, 490  
clinical use for organ transplants, 500–504
- RASI-1**, 13
- Ras** signaling pathways, 23–24
- Ravuconazole**, 898–899
- RB-6145**  
radiosensitizer, 182
- RB-90740**  
radiosensitizer, 181
- Rb gene**, 27  
gene therapy target, 44–45
- RD2-4039**  
hepatitis C antiviral, 421, 423
- RD3-0028**, 394–395
- RD3-4082**  
hepatitis C antiviral, 421, 423
- RD4-6205**  
hepatitis C antiviral, 422, 423
- Reactive oxygen species**, 33
- Receptor interacting protein**, 17
- Receptor tyrosine kinases**  
and angiogenesis, 217–219  
and carcinogenesis, 11–12, 22–23
- Recrudescence**, 922–923
- Reduced folate carrier**, 285
- Reductase** tumor-activated **pro-drugs**, 91–92
- Relenza**, 364
- Remicade**, 229, 233
- (-)-Repandine**  
antimalarial, 997
- Reserpine**  
radioprotective agent, 165
- Resiquimod**  
for herpes, 325
- Resochin**, 934
- RespiGam**, 361, 395
- Respiratory syncytial virus**  
antiviral agents, 390, 398
- Restoration (chemical radioprotection)**, 153
- Restriction fragment length polymorphisms**  
and carcinogenesis, 6
- Retinoblastoma**, 27, 28
- Retroviruses**. *See also* **HIV virus**  
defined, 459  
vectors for cancer gene therapy, 40–42
- RFI-641**, 390–393
- Rhinacanthins**  
influenza antiviral agents, 389
- Rhizopus**, 883
- Rhodacyanine** dye analog, **cationic**  
selective toxicity, 258
- Rhodococcus**  
penicillin-binding protein, 615
- Rhodomyces**  
antitumor natural products, 124, 126
- Riamet**, 935
- Ribavirin**  
activity against **orthopoxviruses**, 439, 440  
**flavivirus** antiviral, 428–429  
for herpes virus, 321

- Ribavirin (Continued)  
 with interferon- $\alpha$  for hepatitis C, 363–364  
 for **poxviruses**, 341
- Riboflavin  
 radiosensitizer, 196
- Ribozymes  
 influenza antiviral agents, 385–386
- Richmond-Sykes classification, of  $\beta$ -lactamases, 619–620
- Rifabutin  
 antimycobacterial application, 811, 847, 850, 852  
 drug interactions, 864  
 efficacy and dosage, 811, 863
- Rifadin, 811
- Rifalazil, 847, 850, 852–853
- Rifampicin  
 antimycobacterial application, 811, 850–852  
 drug interactions, 862, 864  
 efficacy and dosage, 811, 863
- Rifampin, 850  
 drug interactions, 267  
 efficacy and dosage, 811  
 selective toxicity, 266
- Rifamycin B, 847, 848
- Rifamycin O**, 847
- Rifamycin S, 847
- Rifamycins  
 antimycobacterial application, 811, 846–853
- Rifamycin SV, 847, 848  
 efficacy and dosage, 811
- Rifamycin **T9**, 847, 850, 853
- Rifapentine  
 antimycobacterial application, 811, 847, 850, 852  
 efficacy and dosage, 811
- Rifazalil**  
 antimycobacterial application, 859
- Rifocin, 811
- Rimactane, 811
- Rimantadine, 361  
 selective toxicity, 266, 267
- Ringworm/tinea**, 883
- Risedronate  
 selective toxicity, 273
- Ritipenem **acoxil**, 659, 660
- Ritonavir  
 anti-HIV drug, 475–476  
 selective toxicity, 267
- Rituxan, 228, 230
- Rituximab**, 228, 230–231
- RNA polymerases, 295
- RNA viruses, 360–361. See also Antiviral agents, RNA
- Ro-09-3143, 907
- Ro-19-8928**, 678, 680
- Ro-42-1611  
 antimalarial, 984–985
- Ro-48-1220, 710, 711
- Ro-63-9141, 703, 704
- Robustaflavone**  
 influenza antiviral agent, 389
- (-)-**Roemrefidine**  
 antimalarial, 997, 998
- Rofecoxib  
 selective toxicity, 274
- Rokitamycin, 763
- Ros growth factor receptor, 22
- Rotaviruses, 430  
 antiviral agents, 430–431
- Roxithromycin, 763
- RPR103611**  
 anti-HIV drug, 469
- rRNA**  
 bacterial, 738
- RS** 61443, 490, 518, 519
- RSHZ19**  
 RSV antiviral agent, 395
- RSR-13**  
 radiosensitizer, 184–190
- RSU 1069**  
 radiosensitizer, 181–182
- RU 44790, 668, 669
- Rubella virus, 431  
 antiviral agents, 431–432
- Rubex**  
 antitumor natural product, 128
- Rubidomycin  
 antitumor natural product, 126–128
- Rufigallol**  
 antimalarial, 987
- RWJ-54428, 703, 704
- RWJ-270201, 364, 374–376
- RWJ-333441, 703, 704
- S-2242  
 for adenoviruses, 340  
 for herpes virus, 317–318, 321  
 for **poxviruses**, 341
- S-4661, 708
- Saintopin**  
 dual topoisomerase I/II inhibitor, 73
- Sandimmune, 491, 492
- Sanfetrinem, 684, 685, 686, **693–694**  
*in vitro* activity, 692
- Sanitizers, 539
- Saquinavir  
 anti-HIV drug, 475–476  
 selective toxicity, 267
- Sarachine  
 antimalarial, 999
- Satraplatin  
**alkylating agent**, **54, 60**
- SB-206999, 699
- SB-209763  
 RSV antiviral agent, 395
- SB-408075  
 tumor-activated **prodrug**, 83, 94
- SCH 29482, 659, 660, 698
- SCH 34343, 660
- SCH 48973  
 picornavirus antiviral, 400–401
- SCH 68631  
 hepatitis C antiviral, 422, 424
- SCH 351633  
 hepatitis C antiviral, 422, 424
- Schistosomiasis, 1035
- SDZ 880-061  
 picornavirus antiviral, 401–402
- Selective estrogen receptor modulators  
 selective toxicity, 276–277
- Selective toxicity, 250–252  
 aminoglycosides, 260–261  
 antibacterial agents, **539–543**  
 antifungal drugs, 254, 266–268, 886  
 antihistamines, 275–276  
 antiinfectives, 259–263  
 antimycobacterial drugs, 266  
 antiparasite drugs, 254, 268  
 antiviral drugs, 254, 266  
 bisphosphonates, 273–274  
 cancer chemotherapy **examples**, 257–259  
**cationic** rhodacyanine dye analog, 258  
**cisplatin/carboplatin**, **257–258**  
 comparative biochemistry, 253–254  
 comparative cytology, 254  
 comparative distribution, 252–253  
 comparative stereochemistry, 254–257  
 COX inhibitors, 274–275  
 diphtheria toxin, 259  
 and **dopaminergic** receptors, 259



- and drug chirality, 268–273  
 estrogen receptor modulators, 276–277  
 imatinib, 257  
 insect growth regulators, 278  
 insecticides, 277–279  
 **$\beta$ -lactams**, 254, 260  
 macrolides, 261–263  
 monoclonal antibodies, 257  
 neonicotinoids, 278  
**paclitaxel** antibody conjugate, 258  
 phosphodiesterase inhibitors, 277  
**quinolones/fluoroquinolones**, 263  
 spinosyns, 278  
**sulfonamides/sulfanilamides**, 263–264  
 target organism examples, 264–268  
 tetracyclines, 261  
 tricyclic thiophene, 258–259  
 Serial analysis of gene expression (SAGE)  
 cancer studies using, 36–37  
 Serine **kinases**, 24  
 Seromycin, 811  
 Serotonin  
 radioprotective agent, 165, 167  
 Serum complement, 224  
 SGN-15  
 tumor-activated **prodrug**, 83, 92  
 Shingles, 298  
 Siamycin  
 anti-HIV drug, 469  
 Sickle trait  
 and malaria, 931  
 Signal peptidase enzymes, 712  
 Silatecans  
 antitumor natural products, 133  
**Sildenafil**  
 selective toxicity, 277  
 Silver salts  
 topical antibacterials, 553  
 Simulcet, 510, 513  
 Sindbis virus, 431  
 Single nucleotide polymorphism (**SNPs**)  
 and carcinogenesis, 6  
 Sirolimus, 489, 490  
 clinical use for organ transplants, 500–504  
**pharmacokinetics**, 500  
 pharmacology, 500–503  
 side effects, 503–504  
 structure-activity relationship, 503  
 Sis growth factor, 22  
**Skin-derived dendritic (Langerhans)** cells, 224  
 SM 7338, 668–669  
 Smallpox, 435–440  
 SN-24771  
 radiosensitizer, 196  
**SNPs**, See Single nucleotide polymorphisms  
**SO3**  
 antimalarial, 957  
 Sodium cysteinethiosulfate  
 radioprotective agent, 161  
 Sodium 2,3-dimercaptopropane sulfonate  
**radioprotective** agent, 157  
 Sodium selenate  
 radioprotective agent, 162  
 Sodium stibogluconate  
 for leishmaniasis, 1051  
 Solasulfone, 830  
 Soluble intercellular adhesion molecule-1  
 picornavirus antiviral agent, 403–404  
 Sordarins, 907–908  
 Southeast Asian ovalocytosis  
 and malaria, 931  
 Sparfloxacin, 855  
 Spectazole, 891  
 Spergualin, 504  
 Spinosyns  
 selective toxicity, 278  
 Spiramycin, 763  
 Sporanox, 890, 891  
 Sporothrix schenckii, 883  
 Sporotrichosis, 883  
 SQ 26180, 664, 665  
 SQ 83360, 668  
 SR-4233  
 radiosensitizer, 181  
 SR-4482  
 radiosensitizer, 181  
 SR-3727A  
 for herpes virus, 316  
 Src-homology domains, 23, 25  
**Src tyrosine kinase**, 22  
 SRR-SB3  
 anti-HIV drug, 469, 470  
 Stachyflin  
 influenza antiviral agent, 379–380  
 Staphylococcus  
 bridge in peptidoglycans, 612  
 penicillin-binding protein, 615  
 Staphylococcus aureus  
 antibiotics active against, 631–632  
 methicillin-resistant, 617–618  
 Staurosporine  
 radiosensitizer, 193  
 Stavudine  
 selective toxicity, 267  
 Stem cells  
 organ transplant rejection applications, 523–524  
 Sterilization, 539  
**STI571**, 284  
 Streptococcus  
 bridge in peptidoglycans, 612  
 penicillin-binding protein, 615, 617  
 Streptococcus pneumonia  
 **$\beta$ -lactam** resistance, 613, 712  
 Streptogramins, 785–787  
 Streptomyces, 111, 609  
 Streptomyces argillaceus, 122, 123  
 Streptomyces caespitosus, 120  
 Streptomyces peucetius, 124  
 Streptomyces *plicatus*, 122  
 Streptomyces tanashiensis, 123  
 Streptomyces *verticillus*, 115  
 Streptomycin, 748  
 antimycobacterial application, 811, 840–842  
 drug interactions, 864  
 efficacy and dosage, 811, 863  
 mechanism of action, 841–842  
 selective toxicity, 260–261  
 structure-activity relationship, 840–841  
 Streptozotocin  
 alkylating agent, 54, 65  
 Stress proteins, 819  
 Stromelysins, 13  
**SU5416**  
 antiangiogenic agent, 218–219  
**SU6668**  
 antiangiogenic agent, 218–219  
 Suicide gene therapy, 90  
 for cancer, 39, 44  
 Sulbactam, 697  
 amoxicillin MIC, 695  
 antimycobacterial application, 858  
 **$\beta$ -lactamase** inhibitory activity, 695  
 use recommendations, 626

- Sulbenicillin, 632
- Sulconazole, 904  
formulations and indications, 891
- Sulfadoxine, 957  
with **pyrimethamine**, 958–959  
useful lifetime before resistance develops, 930
- Sulfalene, 957  
dosage forms, 935
- Sulfamethoxazole, 957  
dosage forms, 934
- Sulfanilamide  
selective toxicity, 263–264
- Sulfazecin, 609, 664, 665
- Sulfisoxazole, 957  
dosage forms, 934
- Sulfonamides  
antimalarial, 957–958  
selective toxicity, 263–264  
systemic antibacterials, 557–582
- Sulfones  
antimalarial, 957–958  
antimycobacterial, 829–830  
systemic antibacterials, 557–582
- Sulfonylureas  
selective toxicity, 264
- Sulfur-containing compounds  
radioprotective agents, 152, 155–162
- Sultamicillin**, 697
- SUN 5555, 659, 660
- Sunamed, 763, 935
- Suramin  
for African trypanosomiasis, 1037–1039  
antihelmintic, 1091, 1095–1096
- Surfactants  
topical antibacterials, **555–557**
- Synagis**, 227  
RSV antiviral agent, 395
- Synercid, 793
- Synergis, 361
- Synkovit**  
radiosensitizer, 196
- Synthetic antibacterials  
systemic, 557–594  
topical, **539–557**
- T-705  
influenza antiviral agent, 390
- T-5575, 637
- T-5578, 637
- T-157602  
for herpes, 323
- Tacrolimus, 489, 490. See also FK 506  
clinical use for organ transplants, 494–500  
with leflunomide, 523
- Tafenoquine, 953
- Tagamet**  
selective toxicity, 275
- TAK-779  
anti-HIV drug, 468
- Talampicillin, 632
- Tallimustine**  
alkylating agent, 57–58
- Tallysomyins  
antitumor natural products, 115, 117
- Talompicillin, 609
- Tamiflu**, 364
- Tamoxifen**  
selective toxicity, 276
- Targeted mustards, 57
- TAS 103**  
dual topoisomerase I/II inhibitor, 68, 73, 74
- Taxol**  
antitumor natural product, 110, 136–138
- Taxotere  
antimalarial, 990  
antitumor natural product, 138–139
- Taxus** diterpenes  
antitumor natural product, 110, 136–139
- Tazobactam, 697–698  
**amoxycillin** MIC, 695  
antimycobacterial application, 858  
 **$\beta$ -lactamase** inhibitory activity, 695  
use recommendations, 626
- T-cell receptors, 224
- T-cells  
activation by dendritic cells, 235–236  
and adaptive immunity, 224–226  
exosome secretion, 241  
**HIV** infection, 458–464  
organ transplant drugs blocking function, 489–513  
role in organ rejection, 487–488
- Tebrazid, 810
- Tebuquine, 982
- Telithromycin, 763
- Telomerase, 11
- Telomeres, 11
- Teloxantrone  
topoisomerase II inhibitor, 72
- Temacrazine  
anti-HIV drug, 474
- Temocillin, 609, 636  
in *vitro* antibacterial activity, 635
- Temodar  
alkylating agent, 54
- Temozolomide  
alkylating agent, 54, 65, 67
- Tempol**  
radioprotective agent, 163–164, 171
- (+)-**Temuconine**  
antimalarial, 996
- Teniposide  
antitumor natural product, 110, 135–136
- Tenofovir  
anti-HIV drug, 471, 472
- Terazole, 891
- Terbinafine**, 899–900  
formulations and indications, 890, 891  
selective toxicity, 268
- Terconazole, 904  
formulations and indications, 891  
selective toxicity, 268
- Tetracyclines  
antimalarials, 935, 982–983  
biosynthesis, 742–743  
clinical use and currently used **drugs**, 739–741  
drug resistance, 743–746  
pharmacology and mode of action, 741–742  
radioprotective agents, 166  
recent developments, 746–747  
selective toxicity, 261  
side effects, toxicity, and contraindications, 741
- Tetraoxane  
antimalarial, 986
- Tetraplatin  
alkylating agent, 54, 59, 61
- T-helper lymphocytes, 224–225
- Therapeutic gain, **radiosensitizers**, 173
- Thiabendazole  
antihelmintic, 1090–1091, 1091

- Thiamine diphosphate  
radiosensitizer, 196
- Thiazide diuretics  
selective toxicity, 264
- Thienamycin, 609, 669, 670  
activity, 688–693  
synthesis, 672–674
- Thioacetazone, 832  
efficacy and dosage, 810, 863  
side effects, 832–833
- Thiocarbamate antifungal  
agents, 903
- Thiocarlide  
efficacy and dosage, 810
- Thioglycolic acid  
radioprotective agent, 161
- 6-Thioguanine  
antimetabolite, 76, 81
- Thiolactomycins  
antimycobacterial application,  
859–860
- Thiols  
radioprotective agents, 152,  
155–160  
radiosensitizers, 192–193,  
196–197
- Thiourea  
radioprotective agent, 152,  
170
- Threonine **kinases**, 24
- Thrush, 882
- Thymidylate **synthase** inhibitors  
antimetabolites, 76–77
- Thymitaq  
antimetabolite, 76, 79
- Ticarcillin, 632, 633  
antimycobacterial application,  
858  
indications, 625  
**pharmacokinetics**, 624  
use recommendations, 626  
in vitro antibacterial activity,  
635
- Tigemonam, 666  
in vitro activity, 667
- Timentin, 695  
use recommendations, 626
- Timoxicillin, 633
- Tinactin, 891
- Ting, 891
- Tioconazole, 904  
formulations and indications,  
891
- Tipranavir  
**anti-HIV drug**, 476–477
- Tirapazamine  
radiosensitizer, 181
- tumor-activated **prodrug**, 83,  
84, 85, 86
- Tirazone  
tumor-activated **prodrug**, 83
- Tissue inhibitor of matrix **metal-  
loproteinases-1**, 12
- Tissue transplantation, 486
- T-lymphocytes, See T-cells
- TNFR-associated death domain,  
17
- TOC-39, 703, 705
- TOC-50, 703, 705
- Tolnaftate**, 903  
formulations and indications,  
891  
selective toxicity, 268
- Tomudex**  
antimetabolite, 76, 77–78
- Topoisomerase I, 67–68
- Topoisomerase II, 67–68, 135
- Topoisomerase I inhibitors  
**camptothecins**, 131, 132  
dual I/II inhibitors, 72–75
- Topoisomerase II inhibitors  
dual I/II inhibitors, 72–75  
etoposide, 135  
resistance to, 284  
synthetic, 68–72  
tenoposide, 136
- Topotecan  
antitumor natural product,  
110, 131
- Toxicity. *See* also Selective toxic-  
ity; specific drugs and  
classes of drugs  
aminoglycosides, 748–749
- tra genes, 614
- Transforming growth factor  $\beta$ ,  
226  
and carcinogenesis, 30–32
- Transglycosylases, 610  
inhibition of bacterial by  
 **$\beta$ -lactams**, 611–613
- Transpeptidases, 610  
inhibition of bacterial by  
 **$\beta$ -lactams**, 611–613
- Transplant rejection, 486–487
- Trastuzumab, 228, 230  
selective toxicity, 257
- Trecator, 810
- Trevintix, 810
- Triacetyloleandomycin, 763
- Triazenes  
alkylating agents, 54, 65–67
- Triciribine  
for herpes, 322–323
- Tricyclic thiophene  
selective toxicity, 258–259
- Trifluoroperazine  
arenavirus antiviral, 430
- Trimethoprim, 956  
dosage forms, 934  
selective toxicity, 264
- Trimetrexate  
antimetabolite, 76, 79
- Trinems, 609, 683–688  
anti-gram-positive, 703–705  
biological properties, 688–694  
orally active, 709–710
- Trk growth factor, 22
- tRNA**  
bacterial, 738
- Tropical Disease Research List  
(WHO), 1035
- Trovafloxacin**  
**antimalarial**, 983–984
- Tryptanthrin  
antimycobacterial application,  
859
- T-tropic HIV, 468
- Tuberculin, 818–819
- Tuberculosis, 809–813, 1035  
pathogenesis and epidemiol-  
ogy, 821–825  
recent developments and  
present status of chemo-  
therapy, 860–864
- Tubulin  
antitumor natural products  
interfering with, 110,  
136–143
- $\alpha$ -Tubulin, 136
- $\beta$ -Tubulin, 136
- Tubulosine  
antimalarial, 997, 998
- Tumor-activated prodrugs, 44,  
82–83  
for antibody-directed **enzyme-  
prodrug** therapy (ADEPT),  
83, 87–90  
antibody-toxin conjugates  
(armed antibodies), 83,  
92–94  
for gene-directed **enzyme-pro-  
drug** therapy (GDEPT), 83,  
90–92  
hypoxia-activated prodrugs,  
83–87
- Tumorigenesis, 2–3  
and genetic variability, 5–7
- Tumor-infiltrating lymphocytes,  
226
- Tumor lysates, 239–240

- Tumor necrosis factor- $\alpha$   
and mycobacterial infection, 822  
radioprotective agent, 171  
radiosensitizer, 194
- Tumor necrosis factors, 17
- Tumor promoter **TPA-responsive** element, 25
- Tumors, 225–226
- Tumor suppressor genes, 3, 26–32  
methylation and drug resistance, 289  
targeting loss of function, 44–45
- U-100480  
antimycobacterial, 859
- UK-109,496,897
- Ultraviolet radiation  
and carcinogenesis, 4
- Unasyn  
use recommendations, 626
- Undecylenate, 906  
formulations and indications, 891
- Unithiol  
radioprotective agent, 157
- Urethane  
radioprotective agent, 165
- V-002,902
- Vaccinia immune globulin  
for smallpox, 435
- Vaccinia virus  
vector for cancer gene therapy, 41
- Vagistat, 891
- Val-2-AM (dactinomycin), 111
- Valciclovir  
for herpes virus, 309,310
- Valrubicin  
antitumor natural product, 110,124, 128–130
- Vancomycin  
with aztreonam, 625  
in *vivo* efficacy in systemic murine infections, 685
- Vardenafil**  
selective toxicity, 277
- Varicella zoster virus, 298
- Vascular endothelial growth factor, 217–218  
and angiogenesis, 20–21
- Vascular endothelial growth factor inhibitors  
antiangiogenic agents, 218–219
- Veins, 216
- Velban  
antitumor natural product, 140–142
- Verapamil  
selective toxicity, 270–271
- Verazide, 834
- Vfend, 890,897–898
- Viagra**  
selective toxicity, 277
- Vibramycin, 740,935
- Victomycins  
antitumor natural products, 117
- Vidarabine  
for herpes virus, 309,315  
for papillomavirus, 338
- Vinblastine  
antitumor natural product, 110,140–142
- Vinca alkaloids, 52  
antitumor natural product, 110,139–143
- Vincasar PFS**  
antitumor natural product, 142
- Vincristine  
antitumor natural product, 110, 142  
with dactinomycin, 111
- Vindesine  
antitumor natural product, 142
- Vinflunine  
antitumor natural product, 142–143
- Vinorelbine  
antitumor natural product, 110,142–143
- Viomycin  
antimycobacterial application, 811,844–846  
efficacy and dosage, 811,863  
side effects, 845–846
- Vioxx**  
selective toxicity, 274
- Viruses, 294. See also Antiviral agents, DNA; Antiviral agents, RNA  
classes of, 294–305  
progeny production, 295–296
- Vismione H  
antimalarial, 997,998
- Vitamin A family  
antimalarial, 989  
and cancer risk, 33
- Vitamin B<sub>8</sub> family  
radioprotective derivatives, 166
- Vitamin replacement therapy, 251
- Vitamins  
and cancer prevention, 33
- Von Hippel-Lindau gene, 8, 10
- Voriconazole, 897–898  
formulations and indications, 890
- VP-14637, 393**
- V-sis, 22
- VX-497  
hepatitis C virus antiviral agents, 426–427  
for herpes, 322
- Warfarin  
selective toxicity, 271
- Warts, 301
- Wax D, 817
- WAY-150138  
for herpes virus, 314–315
- WAY-154641,390–393
- Wellvone, 935
- West Nile virus, 427, 428
- WIN 5723,853
- WIN 51711  
picornavirus antiviral, 400
- WIN 54954  
picornavirus antiviral, 399
- WIN 59075  
radiosensitizer, 181
- WIN 61893  
picornavirus antiviral, 399
- WMC-26**  
dual topoisomerase I/II inhibitor, 75
- WR1065**  
radioprotective agent, 167–168
- WR2721**  
radioprotective agent, 157, 167,172
- WR33,063**  
antimalarial, 946
- WR99,210**  
antimalarial, 960
- WR122,455**  
antimalarial, 946
- WR148,999**  
antimalarial, 986
- WR182,393**  
antimalarial, 954
- WR225,448**  
antimalarial, 952–953

- WR238,605**  
antimalarial, 952-953
- WR242,511**  
antimalarial, 952-953
- WR250,417**  
antimalarial, 960
- WR268,954**  
antimalarial, 942
- WT-1 gene, 27
- Xanthates  
radioprotective agent,  
161-162
- Xenotransplantation, 489  
future developments, 526
- Xeroderma pigmentosum, 32
- XR-5000**  
dual topoisomerase I/II inhibitor, 68, 73
- XR-5944**  
dual topoisomerase I/II inhibitor, 75
- X-rays. See also Radioprotective agents  
antiradiation testing, 154
- Yellow fever virus, 427
- Yingzhaosu A  
antimalarial, 984-985
- Yingzhaosu C  
antimalarial, 984-985
- Zafirlukast**  
selective toxicity, 252
- Zalcitabine  
anti-HIV drug, 471, 472  
selective toxicity, 267
- Zanamivir**, 361  
for influenza, 365, 368  
selective toxicity, 266, 267
- Zanosar**  
alkylating agent, 54
- ZD-0473**  
alkylating agent, 54, 60, 61
- ZD-1839**, 12
- ZD-2767**  
tumor-activated prodrug, 83, 88
- ZD-4190**  
antiangiogenic agent, 218-219
- Zenepax, 510
- Zidovudine  
anti-HIV drug, 471-472  
selective toxicity, 267
- Zileuton  
selective toxicity, 252
- Zinamide, 810
- Zinc aspartate  
radioprotective agent, 163
- Zithromax, 763, 935
- Zorbamycins**  
antitumor natural products,  
115, 117
- Zorbonamycins  
antitumor natural products,  
117
- Zosyn**  
use recommendations, 626
- Zyrnosterol, 887



“An essential addition to the libraries of any medicinal chemist . . . an outstanding work . . . highly praised as a fountain of information in drug studies and research.”

—*Journal of Medicinal Chemistry* on the *Fifth Edition*

This new edition of Dr. Alfred Burger's internationally celebrated classic helps researchers acquaint themselves with both traditional and state-of-the-art principles and practices governing new medicinal drug research and development. Completely updated and revised to reflect the many monumental changes that have occurred in the field, this latest edition brings together contributions by experts in a wide range of related fields to explore recent advances in the understanding of the structural biology of drug action, as well as cutting-edge technologies for drug discovery now in use around the world.

This *Sixth Edition* of *Burger's Medicinal Chemistry and Drug Discovery* has been expanded to six volumes:

Volume 1: Drug Discovery

Volume 2: Drug Discovery and Drug Development

Volume 3: Cardiovascular Agents and Endocrines

Volume 4: Autocoids, Diagnostics, and Drugs from New Biology

Volume 5: Chemotherapeutic Agents

Volume 6: Nervous System Agents

**DONALD A. ABRAHAM, PHD**, is Professor and Chairman of the Department of Medicinal Chemistry at the Virginia Commonwealth University School of Pharmacy. A world-renowned leader in medicinal chemistry and biotechnology, he is the author of more than 140 journal citations and twenty-five patents. He was selected by the AACP Board of Directors as the recipient of the 2002 AACP Paul Dawson Biotechnology Award.

Cover Design: David Levy

 **WILEY-  
INTERSCIENCE**  
wiley.com

ISBN 0-471-37031-2



9 780471 370314

90000

